<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">35269543</PMID><DateCompleted><Year>2022</Year><Month>03</Month><Day>25</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>25</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>5</Issue><PubDate><Year>2022</Year><Month>Feb</Month><Day>22</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Comprehensive Research on Past and Future Therapeutic Strategies Devoted to Treatment of Amyotrophic Lateral Sclerosis.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">2400</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms23052400</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a rapidly debilitating fatal neurodegenerative disorder, causing muscle atrophy and weakness, which leads to paralysis and eventual death. ALS has a multifaceted nature affected by many pathological mechanisms, including oxidative stress (also via protein aggregation), mitochondrial dysfunction, glutamate-induced excitotoxicity, apoptosis, neuroinflammation, axonal degeneration, skeletal muscle deterioration and viruses. This complexity is a major obstacle in defeating ALS. At present, riluzole and edaravone are the only drugs that have passed clinical trials for the treatment of ALS, notwithstanding that they showed modest benefits in a limited population of ALS. A dextromethorphan hydrobromide and quinidine sulfate combination was also approved to treat pseudobulbar affect (PBA) in the course of ALS. Globally, there is a struggle to prevent or alleviate the symptoms of this neurodegenerative disease, including implementation of antisense oligonucleotides (ASOs), induced pluripotent stem cells (iPSCs), CRISPR-9/Cas technique, non-invasive brain stimulation (NIBS) or ALS-on-a-chip technology. Additionally, researchers have synthesized and screened new compounds to be effective in ALS beyond the drug repurposing strategy. Despite all these efforts, ALS treatment is largely limited to palliative care, and there is a strong need for new therapeutics to be developed. This review focuses on and discusses which therapeutic strategies have been followed so far and what can be done in the future for the treatment of ALS.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sever</LastName><ForeName>Belgin</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0003-4847-9711</Identifier><AffiliationInfo><Affiliation>Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Anadolu University, Eskisehir 26470, Turkey.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medicinal and Biological Chemistry Science Farm Joint Research Laboratory, Faculty of Life Sciences, Kumamoto University, Kumamoto 862-0973, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ciftci</LastName><ForeName>Halilibrahim</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-9796-7669</Identifier><AffiliationInfo><Affiliation>Medicinal and Biological Chemistry Science Farm Joint Research Laboratory, Faculty of Life Sciences, Kumamoto University, Kumamoto 862-0973, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Drug Discovery, Science Farm Ltd., Kumamoto 862-0976, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Molecular Biology and Genetics, Koc University, Istanbul 34450, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DeMirci</LastName><ForeName>Hasan</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-9135-5397</Identifier><AffiliationInfo><Affiliation>Department of Molecular Biology and Genetics, Koc University, Istanbul 34450, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sever</LastName><ForeName>Hilal</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Ministry of Health, Istanbul Training and Research Hospital, Physical Medicine and Rehabilitation Clinic, Istanbul 34098, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ocak</LastName><ForeName>Firdevs</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, Kocaeli University, Kocaeli 41001, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yulug</LastName><ForeName>Burak</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neuroscience, Faculty of Medicine, Alaaddin Keykubat University, Alanya 07425, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tateishi</LastName><ForeName>Hiroshi</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0003-1225-0720</Identifier><AffiliationInfo><Affiliation>Medicinal and Biological Chemistry Science Farm Joint Research Laboratory, Faculty of Life Sciences, Kumamoto University, Kumamoto 862-0973, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tateishi</LastName><ForeName>Takahisa</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Division of Respirology, Neurology and Rheumatology, Department of Medicine, Kurume University School of Medicine, Fukuoka 830-0011, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Otsuka</LastName><ForeName>Masami</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Medicinal and Biological Chemistry Science Farm Joint Research Laboratory, Faculty of Life Sciences, Kumamoto University, Kumamoto 862-0973, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Drug Discovery, Science Farm Ltd., Kumamoto 862-0976, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fujita</LastName><ForeName>Mikako</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-6705-4052</Identifier><AffiliationInfo><Affiliation>Medicinal and Biological Chemistry Science Farm Joint Research Laboratory, Faculty of Life Sciences, Kumamoto University, Kumamoto 862-0973, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ba&#x15f;ak</LastName><ForeName>Ay&#x15f;e Nazl&#x131;</ForeName><Initials>AN</Initials><Identifier Source="ORCID">0000-0001-6977-2517</Identifier><AffiliationInfo><Affiliation>Suna and &#x130;nan K&#x131;ra&#xe7; Foundation, Neurodegeneration Research Laboratory (KUTTAM-NDAL), Koc University, Istanbul 34450, Turkey.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>02</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>7LJ087RS6F</RegistryNumber><NameOfSubstance UI="D019782">Riluzole</NameOfSubstance></Chemical><Chemical><RegistryNumber>S798V6YJRP</RegistryNumber><NameOfSubstance UI="D000077553">Edaravone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D046690" MajorTopicYN="N">Deep Brain Stimulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055808" MajorTopicYN="N">Drug Discovery</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077553" MajorTopicYN="N">Edaravone</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057026" MajorTopicYN="N">Induced Pluripotent Stem Cells</DescriptorName><QualifierName UI="Q000637" MajorTopicYN="N">transplantation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019782" MajorTopicYN="N">Riluzole</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis (ALS)</Keyword><Keyword MajorTopicYN="N">apoptosis</Keyword><Keyword MajorTopicYN="N">axonal degeneration</Keyword><Keyword MajorTopicYN="N">edaravone</Keyword><Keyword MajorTopicYN="N">glutamate excitotoxicity</Keyword><Keyword MajorTopicYN="N">induced pluripotent stem cells (iPSCs)</Keyword><Keyword MajorTopicYN="N">neuroinflammation</Keyword><Keyword MajorTopicYN="N">oxidative stress</Keyword><Keyword MajorTopicYN="N">protein aggregation</Keyword><Keyword MajorTopicYN="N">riluzole</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>1</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>2</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>2</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>3</Month><Day>10</Day><Hour>15</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>3</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>3</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35269543</ArticleId><ArticleId IdType="pmc">PMC8910198</ArticleId><ArticleId IdType="doi">10.3390/ijms23052400</ArticleId><ArticleId IdType="pii">ijms23052400</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Liu J., Wang F. Role of neuroinflammation in amyotrophic lateral sclerosis: Cellular mechanisms and therapeutic implications. Front. Immunol. 2017;8:1005. doi: 10.3389/fimmu.2017.01005.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2017.01005</ArticleId><ArticleId IdType="pmc">PMC5567007</ArticleId><ArticleId IdType="pubmed">28871262</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez A., Palomo Ruiz M.D., Perez D.I., Gil C. Drugs in clinical development for the treatment of amyotrophic lateral sclerosis. Expert Opin. Investig. Drugs. 2017;26:403&#x2013;414. doi: 10.1080/13543784.2017.1302426.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/13543784.2017.1302426</ArticleId><ArticleId IdType="pubmed">28277881</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon P.H. Amyotrophic lateral sclerosis: Pathophysiology, diagnosis and management. CNS Drugs. 2011;25:1&#x2013;15. doi: 10.2165/11586000-000000000-00000.</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/11586000-000000000-00000</ArticleId><ArticleId IdType="pubmed">21128691</ArticleId></ArticleIdList></Reference><Reference><Citation>Harikrishnareddy D., Misra S., Upadhyay S., Modi M., Medhi B. Roots to start research in amyotrophic lateral sclerosis: Molecular pathways and novel therapeutics for future. Rev. Neurosci. 2015;26:161&#x2013;181. doi: 10.1515/revneuro-2014-0057.</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/revneuro-2014-0057</ArticleId><ArticleId IdType="pubmed">25720096</ArticleId></ArticleIdList></Reference><Reference><Citation>Sardana D., Zhu C., Zhang M., Gudivada R.C., Yang L., Jegga A.G. Drug repositioning for orphan diseases. Brief. Bioinform. 2011;12:346&#x2013;356. doi: 10.1093/bib/bbr021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bib/bbr021</ArticleId><ArticleId IdType="pubmed">21504985</ArticleId></ArticleIdList></Reference><Reference><Citation>Longinetti E., Fang F. Epidemiology of amyotrophic lateral sclerosis: An update of recent literature. Curr. Opin. Neurol. 2019;32:771&#x2013;776. doi: 10.1097/WCO.0000000000000730.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WCO.0000000000000730</ArticleId><ArticleId IdType="pmc">PMC6735526</ArticleId><ArticleId IdType="pubmed">31361627</ArticleId></ArticleIdList></Reference><Reference><Citation>Root J., Merino P., Nuckols A., Johnson M., Kukar T. Lysosome dysfunction as a cause of neurodegenerative diseases: Lessons from frontotemporal dementia and amyotrophic lateral sclerosis. Neurobiol. Dis. 2021;154:105360. doi: 10.1016/j.nbd.2021.105360.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2021.105360</ArticleId><ArticleId IdType="pmc">PMC8113138</ArticleId><ArticleId IdType="pubmed">33812000</ArticleId></ArticleIdList></Reference><Reference><Citation>Pawlyk A.C., Cassel J.A., Reitz A.B. Current nervous system related drug targets for the treatment of amyotrophic lateral sclerosis. Curr. Pharm. Des. 2010;16:2053&#x2013;2073. doi: 10.2174/138161210791293024.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/138161210791293024</ArticleId><ArticleId IdType="pubmed">20370663</ArticleId></ArticleIdList></Reference><Reference><Citation>Pham J., Keon M., Brennan S., Saksena N. Connecting RNA-modifying similarities of TDP-43, FUS, and SOD1 with microRNA dysregulation amidst a renewed network perspective of amyotrophic lateral sclerosis. Proteinopathy. Int. J. Mol. Sci. 2020;21:3464. doi: 10.3390/ijms21103464.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21103464</ArticleId><ArticleId IdType="pmc">PMC7278980</ArticleId><ArticleId IdType="pubmed">32422969</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowland L.P., Shneider N.A. Amyotrophic lateral sclerosis. N. Engl. J. Med. 2001;344:1688&#x2013;1700. doi: 10.1056/NEJM200105313442207.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM200105313442207</ArticleId><ArticleId IdType="pubmed">11386269</ArticleId></ArticleIdList></Reference><Reference><Citation>Bradley W.G., Mash D.C. Beyond Guam: The cyanobacteria/BMAA hypothesis of the cause of ALS and other neurodegenerative diseases. Amyotroph. Lateral Scler. 2009;2:7&#x2013;20. doi: 10.3109/17482960903286009.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482960903286009</ArticleId><ArticleId IdType="pubmed">19929726</ArticleId></ArticleIdList></Reference><Reference><Citation>Habib A.A., Mitsumoto H. Emerging drugs for amyotrophic lateral sclerosis. Expert Opin. Emerg. Drugs. 2011;16:537&#x2013;558. doi: 10.1517/14728214.2011.604312.</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/14728214.2011.604312</ArticleId><ArticleId IdType="pubmed">21806316</ArticleId></ArticleIdList></Reference><Reference><Citation>Byrne S., Jordan I., Elamin M., Hardiman O. Age at onset of amyotrophic lateral sclerosis is proportional to life expectancy. Amyotroph. Lateral Scler. Front. Degener. 2013;14:604&#x2013;607. doi: 10.3109/21678421.2013.809122.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2013.809122</ArticleId><ArticleId IdType="pubmed">23895536</ArticleId></ArticleIdList></Reference><Reference><Citation>Farace C., Fenu G., Lintas S., Oggiano R., Pisano A., Sabalic A., Solinas G., Bocca B., Forte G., Madeddu R. Amyotrophic lateral sclerosis and lead: A systematic update. NeuroToxicology. 2020;81:80&#x2013;88. doi: 10.1016/j.neuro.2020.09.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuro.2020.09.003</ArticleId><ArticleId IdType="pubmed">32941938</ArticleId></ArticleIdList></Reference><Reference><Citation>Okano H., Yasuda D., Fujimori K., Morimoto S., Takahashi S. Ropinirole, a new ALS drug candidate developed using iPSCs. Trends Pharmacol. Sci. 2020;41:99&#x2013;109. doi: 10.1016/j.tips.2019.12.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tips.2019.12.002</ArticleId><ArticleId IdType="pubmed">31926602</ArticleId></ArticleIdList></Reference><Reference><Citation>Costa J., Gomes C., de Carvalho M. Diagnosis, pathogenesis and therapeutic targets in amyotrophic lateral sclerosis. CNS Neurol. Disord. Drug Targets. 2010;9:764&#x2013;778. doi: 10.2174/187152710793237502.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/187152710793237502</ArticleId><ArticleId IdType="pubmed">20942786</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Harten A.C.M., Phatnani H., Przedborski S. Non-cell-autonomous pathogenic mechanisms in amyotrophic lateral sclerosis. Trends Neurosci. 2021;44:658&#x2013;668. doi: 10.1016/j.tins.2021.04.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2021.04.008</ArticleId><ArticleId IdType="pubmed">34006386</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakagawa Y., Yamada S. A novel hypothesis on metal dyshomeostasis and mitochondrial dysfunction in amyotrophic lateral sclerosis: Potential pathogenetic mechanism and therapeutic implications. Eur. J. Pharmacol. 2021;892:173737. doi: 10.1016/j.ejphar.2020.173737.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejphar.2020.173737</ArticleId><ArticleId IdType="pubmed">33220280</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurney M.E., Pu H., Chiu A.Y., Dal Canto M.C., Polchow C.Y., Alexander D.D., Caliendo J., Hentati A., Kwon Y.W., Deng H.X., et al. Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. Science. 1994;264:1772&#x2013;1775. doi: 10.1126/science.8209258.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.8209258</ArticleId><ArticleId IdType="pubmed">8209258</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M. Lost in translation: Treatment trials in the SOD1 mouse and in human ALS. Neurobiol. Dis. 2007;26:1&#x2013;13. doi: 10.1016/j.nbd.2006.12.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2006.12.015</ArticleId><ArticleId IdType="pubmed">17300945</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomes C., Escrevente C., Costa J. Mutant superoxide dismutase 1 overexpression in NSC-34 cells: Effect of trehalose on aggregation, TDP-43 localization and levels of co-expressed glycoproteins. Neurosci. Lett. 2010;475:145&#x2013;149. doi: 10.1016/j.neulet.2010.03.065.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2010.03.065</ArticleId><ArticleId IdType="pubmed">20363292</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A., Mazzini L., Mora G. Disease-modifying therapies in amyotrophic lateral sclerosis. Neuropharmacology. 2020;167:107986. doi: 10.1016/j.neuropharm.2020.107986.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2020.107986</ArticleId><ArticleId IdType="pubmed">32062193</ArticleId></ArticleIdList></Reference><Reference><Citation>Menzies F.M., Cookson M.R., Taylor R.W., Turnbull D.M., Chrzanowska-Lightowlers Z.M., Dong L., Figlewicz D.A., Shaw P.J. Mitochondrial dysfunction in a cell culture model of familial amyotrophic lateral sclerosis. Brain. 2002;125:1522&#x2013;1533. doi: 10.1093/brain/awf167.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awf167</ArticleId><ArticleId IdType="pubmed">12077002</ArticleId></ArticleIdList></Reference><Reference><Citation>Goos M., Zech W.D., Jaiswal M.K., Balakrishnan S., Ebert S., Mitchell T., Carr&#xec; M.T., Keller B.U., Nau R. Expression of a Cu, Zn superoxide dismutase typical for familial amyotrophic lateral sclerosis increases the vulnerability of neuroblastoma cells to infectious injury. BMC Infect. Dis. 2007;7:131. doi: 10.1186/1471-2334-7-131.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2334-7-131</ArticleId><ArticleId IdType="pmc">PMC2211486</ArticleId><ArticleId IdType="pubmed">17997855</ArticleId></ArticleIdList></Reference><Reference><Citation>Hergesheimer R., Lanznaster D., Vourc&#x2019;h P., Andres C., Bakkouche S., Beltran S., Blasco H., Corcia P., Couratier P. Advances in disease-modifying pharmacotherapies for the treatment of amyotrophic lateral sclerosis. Expert Opin. Pharmacother. 2020;21:1103&#x2013;1110. doi: 10.1080/14656566.2020.1746270.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14656566.2020.1746270</ArticleId><ArticleId IdType="pubmed">32242755</ArticleId></ArticleIdList></Reference><Reference><Citation>Masrori P., Van Damme P. Amyotrophic lateral sclerosis: A clinical review. Eur. J. Neurol. 2020;27:1918&#x2013;1929. doi: 10.1111/ene.14393.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.14393</ArticleId><ArticleId IdType="pmc">PMC7540334</ArticleId><ArticleId IdType="pubmed">32526057</ArticleId></ArticleIdList></Reference><Reference><Citation>Behl T., Kaur G., Sehgal A., Bhardwaj S., Singh S., Buhas C., Judea-Pusta C., Uivarosan D., Munteanu M.A., Bungau S. Multifaceted role of matrix metalloproteinases in neurodegenerative diseases: Pathophysiological and therapeutic perspectives. Int. J. Mol. Sci. 2021;22:1413. doi: 10.3390/ijms22031413.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22031413</ArticleId><ArticleId IdType="pmc">PMC7866808</ArticleId><ArticleId IdType="pubmed">33573368</ArticleId></ArticleIdList></Reference><Reference><Citation>Smart Servier Medical Art.  [(accessed on 4 November 2021)].  Available online:  https://smart.servier.com/</Citation></Reference><Reference><Citation>Fang X. Potential role of gut microbiota and tissue barriers in Parkinson&#x2019;s disease and amyotrophic lateral sclerosis. Int. J. Neurosci. 2016;126:771&#x2013;776. doi: 10.3109/00207454.2015.1096271.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/00207454.2015.1096271</ArticleId><ArticleId IdType="pubmed">26381230</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu S., Yi J., Zhang Y.G., Zhou J., Sun J. Leaky intestine and impaired microbiome in an amyotrophic lateral sclerosis mouse model. Physiol. Rep. 2015;3:e12356. doi: 10.14814/phy2.12356.</Citation><ArticleIdList><ArticleId IdType="doi">10.14814/phy2.12356</ArticleId><ArticleId IdType="pmc">PMC4425962</ArticleId><ArticleId IdType="pubmed">25847918</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng Q., Shen J., Chen K., Zhou J., Liao Q., Lu K., Yuan J., Bi F. The alteration of gut microbiome and metabolism in amyotrophic lateral sclerosis patients. Sci. Rep. 2020;10:12998. doi: 10.1038/s41598-020-69845-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-69845-8</ArticleId><ArticleId IdType="pmc">PMC7398913</ArticleId><ArticleId IdType="pubmed">32747678</ArticleId></ArticleIdList></Reference><Reference><Citation>Niccolai E., Di Pilato V., Nannini G., Baldi S., Russo E., Zucchi E., Martinelli I., Menicatti M., Bartolucci G., Mandrioli J., et al. The gut microbiota-immunity axis in ALS: A role in deciphering disease heterogeneity? Biomedicines. 2021;9:753. doi: 10.3390/biomedicines9070753.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines9070753</ArticleId><ArticleId IdType="pmc">PMC8301418</ArticleId><ArticleId IdType="pubmed">34209688</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicholson K., Bjornevik K., Abu-Ali G., Chan J., Cortese M., Dedi B., Jeon M., Xavier R., Huttenhower C., Ascherio A., et al. The human gut microbiota in people with amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Front. Degener. 2021;22:186&#x2013;194. doi: 10.1080/21678421.2020.1828475.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2020.1828475</ArticleId><ArticleId IdType="pubmed">33135936</ArticleId></ArticleIdList></Reference><Reference><Citation>Garbuzova-Davis S., Haller E., Saporta S., Kolomey I., Nicosia S.V., Sanberg P.R. Ultrastructure of blood-brain barrier and blood-spinal cord barrier in SOD1 mice modeling ALS. Brain Res. 2007;1157:126&#x2013;137. doi: 10.1016/j.brainres.2007.04.044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2007.04.044</ArticleId><ArticleId IdType="pubmed">17512910</ArticleId></ArticleIdList></Reference><Reference><Citation>Abrahao A., Meng Y., Llinas M., Huang Y., Hamani C., Mainprize T., Aubert I., Heyn C., Black S.E., Hynynen K., et al. First-in-human trial of blood-brain barrier opening in amyotrophic lateral sclerosis using MR-guided focused ultrasound. Nat. Commun. 2019;10:4373. doi: 10.1038/s41467-019-12426-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-12426-9</ArticleId><ArticleId IdType="pmc">PMC6763482</ArticleId><ArticleId IdType="pubmed">31558719</ArticleId></ArticleIdList></Reference><Reference><Citation>Barp A., Gerardi F., Lizio A., Sansone V.A., Lunetta C. Emerging drugs for the treatment of amyotrophic lateral sclerosis: A focus on recent phase 2 trials. Expert Opin. Emerg. Drugs. 2020;25:145&#x2013;164. doi: 10.1080/14728214.2020.1769067.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14728214.2020.1769067</ArticleId><ArticleId IdType="pubmed">32456491</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaiswal M.K. Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs. Med. Res. Rev. 2019;39:733&#x2013;748. doi: 10.1002/med.21528.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/med.21528</ArticleId><ArticleId IdType="pubmed">30101496</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang C.Y., Ting H.C., Liu C.A., Su H.L., Chiou T.W., Lin S.Z., Harn H.J., Ho T.J. Induced pluripotent stem cell (iPSC)-based neurodegenerative disease models for phenotype recapitulation and drug screening. Molecules. 2020;25:2000. doi: 10.3390/molecules25082000.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules25082000</ArticleId><ArticleId IdType="pmc">PMC7221979</ArticleId><ArticleId IdType="pubmed">32344649</ArticleId></ArticleIdList></Reference><Reference><Citation>Vasques J.F., Mendez-Otero R., Gubert F. Modeling ALS using iPSCs: Is it possible to reproduce the phenotypic variations observed in patients in vitro? Regen. Med. 2020;15:1919&#x2013;1933. doi: 10.2217/rme-2020-0067.</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/rme-2020-0067</ArticleId><ArticleId IdType="pubmed">32795164</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonaventura G., Iemmolo R., Attaguile G.A., La Cognata V., Pistone B.S., Raudino G., D&#x2019;Agata V., Cantarella G., Barcellona M.L., Cavallaro S. iPSCs: A preclinical drug research tool for neurological disorders. Int. J. Mol. Sci. 2021;22:4596. doi: 10.3390/ijms22094596.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22094596</ArticleId><ArticleId IdType="pmc">PMC8123805</ArticleId><ArticleId IdType="pubmed">33925625</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferraiuolo L., Maragakis N.J. Mini-Review: Induced pluripotent stem cells and the search for new cell-specific ALS therapeutic targets. Neurosci. Lett. 2021;755:135911. doi: 10.1016/j.neulet.2021.135911.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2021.135911</ArticleId><ArticleId IdType="pubmed">33892003</ArticleId></ArticleIdList></Reference><Reference><Citation>Je G., Keyhanian K., Ghasemi M. Overview of stem cells therapy in amyotrophic lateral sclerosis. Neurol. Res. 2021;43:616&#x2013;632. doi: 10.1080/01616412.2021.1893564.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/01616412.2021.1893564</ArticleId><ArticleId IdType="pubmed">33632084</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L., Yi F., Fu L., Yang J., Wang S., Wang Z., Suzuki K., Sun L., Xu X., Yu Y., et al. CRISPR/Cas9-mediated targeted gene correction in amyotrophic lateral sclerosis patient iPSCs. Protein Cell. 2017;8:365&#x2013;378. doi: 10.1007/s13238-017-0397-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13238-017-0397-3</ArticleId><ArticleId IdType="pmc">PMC5413600</ArticleId><ArticleId IdType="pubmed">28401346</ArticleId></ArticleIdList></Reference><Reference><Citation>Osaki T., Uzel S.G.M., Kamm R.D. Microphysiological 3D model of amyotrophic lateral sclerosis (ALS) from human iPS-derived muscle cells and optogenetic motor neurons. Sci. Adv. 2018;4:eaat5847. doi: 10.1126/sciadv.aat5847.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.aat5847</ArticleId><ArticleId IdType="pmc">PMC6179377</ArticleId><ArticleId IdType="pubmed">30324134</ArticleId></ArticleIdList></Reference><Reference><Citation>Edmond E.C., Stagg C.J., Turner M.R. Therapeutic non-invasive brain stimulation in amyotrophic lateral sclerosis: Rationale, methods and experience. J. Neurol. Neurosurg. Psychiatry. 2019;90:1131&#x2013;1138. doi: 10.1136/jnnp-2018-320213.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2018-320213</ArticleId><ArticleId IdType="pubmed">31072957</ArticleId></ArticleIdList></Reference><Reference><Citation>Barber S.C., Shaw P.J. Oxidative stress in ALS: Key role in motor neuron injury and therapeutic target. Free Radic. Biol. Med. 2010;48:629&#x2013;641. doi: 10.1016/j.freeradbiomed.2009.11.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2009.11.018</ArticleId><ArticleId IdType="pubmed">19969067</ArticleId></ArticleIdList></Reference><Reference><Citation>Obrador E., Salvador R., L&#xf3;pez-Blanch R., Jihad-Jebbar A., Vall&#xe9;s S.L., Estrela J.M. Oxidative stress, neuroinflammation and mitochondria in the pathophysiology of amyotrophic lateral sclerosis. Antioxidants. 2020;9:901. doi: 10.3390/antiox9090901.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antiox9090901</ArticleId><ArticleId IdType="pmc">PMC7555310</ArticleId><ArticleId IdType="pubmed">32971909</ArticleId></ArticleIdList></Reference><Reference><Citation>Harley J., Clarke B.E., Patani R. The interplay of RNA binding proteins, oxidative stress and mitochondrial dysfunction in ALS. Antioxidants. 2021;10:552. doi: 10.3390/antiox10040552.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antiox10040552</ArticleId><ArticleId IdType="pmc">PMC8066094</ArticleId><ArticleId IdType="pubmed">33918215</ArticleId></ArticleIdList></Reference><Reference><Citation>Obrador E., Salvador-Palmer R., L&#xf3;pez-Blanch R., Jihad-Jebbar A., Vall&#xe9;s S.L., Estrela J.M. The link between oxidative stress, redox status, bioenergetics and mitochondria in the pathophysiology of ALS. Int. J. Mol. Sci. 2021;22:6352. doi: 10.3390/ijms22126352.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22126352</ArticleId><ArticleId IdType="pmc">PMC8231819</ArticleId><ArticleId IdType="pubmed">34198557</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe K., Morinaka Y., Iseki K., Watanabe T., Yuki S., Nishi H. Structure-activity relationship of 3-methyl-1-phenyl-2-pyrazolin-5-one (edaravone) Redox Rep. 2003;8:151&#x2013;155. doi: 10.1179/135100003225001520.</Citation><ArticleIdList><ArticleId IdType="doi">10.1179/135100003225001520</ArticleId><ArticleId IdType="pubmed">12935312</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe K., Tanaka M., Yuki S., Hirai M., Yamamoto Y. How is edaravone effective against acute ischemic stroke and amyotrophic lateral sclerosis? J. Clin. Biochem. Nutr. 2018;62:20&#x2013;38. doi: 10.3164/jcbn.17-62.</Citation><ArticleIdList><ArticleId IdType="doi">10.3164/jcbn.17-62</ArticleId><ArticleId IdType="pmc">PMC5773834</ArticleId><ArticleId IdType="pubmed">29371752</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakagawa H., Ohyama R., Kimata A., Suzuki T., Miyata N. Hydroxyl radical scavenging by edaravone derivatives: Efficient scavenging by 3-methyl-1-(pyridin-2-yl)-5-pyrazolone with an intramolecular base. Bioorg. Med. Chem. Lett. 2006;16:5939&#x2013;5942. doi: 10.1016/j.bmcl.2006.09.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bmcl.2006.09.005</ArticleId><ArticleId IdType="pubmed">16997555</ArticleId></ArticleIdList></Reference><Reference><Citation>Nayak M., Batchu H., Batra S. Straightforward copper-catalyzed synthesis of pyrrolopyrazoles from halogenated pyrazolecarbaldehydes. Tetrahedron Lett. 2012;53:4206&#x2013;4208. doi: 10.1016/j.tetlet.2012.05.148.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tetlet.2012.05.148</ArticleId></ArticleIdList></Reference><Reference><Citation>Vijay K., Nandi C., Samant S.D. Synthesis of a dihydroquinoline based merocyanine as a &#x2018;naked eye&#x2019; and &#x2018;fluorogenic&#x2019; sensor for hydrazine hydrate in aqueous medium and hydrazine gas. RSC Adv. 2014;4:30712&#x2013;30717. doi: 10.1039/C4RA02426E.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/C4RA02426E</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshino H., Kimura A. Investigation of the therapeutic effects of edaravone, a free radical scavenger, on amyotrophic lateral sclerosis (Phase II study) Amyotroph. Lateral Scler. 2006;7:241&#x2013;245. doi: 10.1080/17482960600881870.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17482960600881870</ArticleId><ArticleId IdType="pubmed">17127563</ArticleId></ArticleIdList></Reference><Reference><Citation>Writing Group. Edaravone (MCI-186) ALS 19 Study Group Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: A randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16:505&#x2013;512. doi: 10.1016/S1474-4422(17)30115-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(17)30115-1</ArticleId><ArticleId IdType="pubmed">28522181</ArticleId></ArticleIdList></Reference><Reference><Citation>Takei K., Watanabe K., Yuki S., Akimoto M., Sakata T., Palumbo J. Edaravone and its clinical development for amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Front. Degener. 2017;18:5&#x2013;10. doi: 10.1080/21678421.2017.1353101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2017.1353101</ArticleId><ArticleId IdType="pubmed">28872907</ArticleId></ArticleIdList></Reference><Reference><Citation>Dash R.P., Babu R.J., Srinivas N.R. Two decades-long journey from riluzole to edaravone: Revisiting the clinical pharmacokinetics of the only two amyotrophic lateral sclerosis therapeutics. Clin. Pharmacokinet. 2018;57:1385&#x2013;1398. doi: 10.1007/s40262-018-0655-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40262-018-0655-4</ArticleId><ArticleId IdType="pubmed">29682695</ArticleId></ArticleIdList></Reference><Reference><Citation>Bailly C., Hecquet P.E., Kouach M., Thuru X., Goossens J.F. Chemical reactivity and uses of 1-phenyl-3-methyl-5-pyrazolone (PMP), also known as edaravone. Bioorg. Med. Chem. 2020;28:115463. doi: 10.1016/j.bmc.2020.115463.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bmc.2020.115463</ArticleId><ArticleId IdType="pubmed">32241621</ArticleId></ArticleIdList></Reference><Reference><Citation>Pattee G.L., Post G.R., Gerber R.E., Bennett J.P., Jr. Reduction of oxidative stress in amyotrophic lateral sclerosis following pramipexole treatment. Amyotroph. Lateral Scler. Other Mot. Neuron Disord. 2003;4:90&#x2013;95. doi: 10.1080/14660820310012736.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14660820310012736</ArticleId><ArticleId IdType="pubmed">14506939</ArticleId></ArticleIdList></Reference><Reference><Citation>Danzeisen R., Schwalenstoecker B., Gillardon F., Buerger E., Krzykalla V., Klinder K., Schild L., Hengerer B., Ludolph A.C., Dorner-Ciossek C., et al. Targeted antioxidative and neuroprotective properties of the dopamine agonist pramipexole and its nondopaminergic enantiomer SND919CL2x [(+)2-amino-4,5,6,7-tetrahydro-6-Lpropylamino-benzathiazole dihydrochloride] J. Pharmacol. Exp. Ther. 2006;316:189&#x2013;199. doi: 10.1124/jpet.105.092312.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/jpet.105.092312</ArticleId><ArticleId IdType="pubmed">16188953</ArticleId></ArticleIdList></Reference><Reference><Citation>Cudkowicz M.E., van den Berg L.H., Shefner J.M., Mitsumoto H., Mora J.S., Ludolph A., Hardiman O., Bozik M.E., Ingersoll E.W., Archibald D., et al. Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): A randomised, double-blind, phase 3 trial. Lancet Neurol. 2013;12:1059&#x2013;1067. doi: 10.1016/S1474-4422(13)70221-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(13)70221-7</ArticleId><ArticleId IdType="pubmed">24067398</ArticleId></ArticleIdList></Reference><Reference><Citation>Cudkowicz M., Bozik M.E., Ingersoll E.W., Miller R., Mitsumoto H., Shefner J., Moore D.H., Schoenfeld D., Mather J.L., Archibald D., et al. The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis. Nat. Med. 2011;17:1652&#x2013;1656. doi: 10.1038/nm.2579.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.2579</ArticleId><ArticleId IdType="pubmed">22101764</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka K., Kanno T., Yanagisawa Y., Yasutake K., Hadano S., Yoshii F., Ikeda J.E. Bromocriptine methylate suppresses glial inflammation and moderates disease progression in a mouse model of amyotrophic lateral sclerosis. Exp. Neurol. 2011;232:41&#x2013;52. doi: 10.1016/j.expneurol.2011.08.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2011.08.001</ArticleId><ArticleId IdType="pubmed">21867702</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagata E., Ogino M., Iwamoto K., Kitagawa Y., Iwasaki Y., Yoshii F., Ikeda J.E., ALS Consortium Investigators Bromocriptine mesylate attenuates amyotrophic lateral sclerosis: A phase 2a, randomized, double-blind, placebo-controlled research in Japanese patients. PLoS ONE. 2016;11:e0149509. doi: 10.1371/journal.pone.0149509.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0149509</ArticleId><ArticleId IdType="pmc">PMC4765990</ArticleId><ArticleId IdType="pubmed">26910108</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujimori K., Ishikawa M., Otomo A., Atsuta N., Nakamura R., Akiyama T., Hadano S., Aoki M., Saya H., Sobue G., et al. Modeling sporadic ALS in iPSC-derived motor neurons identifies a potential therapeutic agent. Nat. Med. 2018;24:1579&#x2013;1589. doi: 10.1038/s41591-018-0140-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-018-0140-5</ArticleId><ArticleId IdType="pubmed">30127392</ArticleId></ArticleIdList></Reference><Reference><Citation>Morimoto S., Takahashi S., Fukushima K., Saya H., Suzuki N., Aoki M., Okano H., Nakahara J. Ropinirole hydrochloride remedy for amyotrophic lateral sclerosis - Protocol for a randomized, double-blind, placebo-controlled, single-center, and open-label continuation phase I/IIa clinical trial (ROPALS trial) Regen. Ther. 2019;11:143&#x2013;166. doi: 10.1016/j.reth.2019.07.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.reth.2019.07.002</ArticleId><ArticleId IdType="pmc">PMC6661418</ArticleId><ArticleId IdType="pubmed">31384636</ArticleId></ArticleIdList></Reference><Reference><Citation>Bucchia M., Ramirez A., Parente V., Simone C., Nizzardo M., Magri F., Dametti S., Corti S. Therapeutic development in amyotrophic lateral sclerosis. Clin. Ther. 2015;37:668&#x2013;680. doi: 10.1016/j.clinthera.2014.12.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinthera.2014.12.020</ArticleId><ArticleId IdType="pubmed">25666449</ArticleId></ArticleIdList></Reference><Reference><Citation>Waibel S., Reuter A., Malessa S., Blaugrund E., Ludolph A.C. Rasagiline alone and in combination with riluzole prolongs survival in an ALS mouse model. J. Neurol. 2004;251:1080&#x2013;1084. doi: 10.1007/s00415-004-0481-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-004-0481-5</ArticleId><ArticleId IdType="pubmed">15372249</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludolph A.C., Schuster J., Dorst J., Dupuis L., Dreyhaupt J., Weishaupt J.H., Kassubek J., Weiland U., Petri S., Meyer T., et al. Safety and efficacy of rasagiline as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: A randomised, double-blind, parallel-group, placebo-controlled, phase 2 trial. Lancet Neurol. 2018;17:681&#x2013;688. doi: 10.1016/S1474-4422(18)30176-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30176-5</ArticleId><ArticleId IdType="pubmed">29934198</ArticleId></ArticleIdList></Reference><Reference><Citation>Statland J.M., Moore D., Wang Y., Walsh M., Mozaffar T., Elman L., Nations S.P., Mitsumoto H., Fernandes J.A., Saperstein D., et al. Rasagiline for amyotrophic lateral sclerosis: A randomized, controlled trial. Muscle Nerve. 2019;59:201&#x2013;207. doi: 10.1002/mus.26335.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.26335</ArticleId><ArticleId IdType="pmc">PMC6545236</ArticleId><ArticleId IdType="pubmed">30192007</ArticleId></ArticleIdList></Reference><Reference><Citation>Lange D.J., Murphy P.L., Diamond B., Appel V., Lai E.C., Younger D.S., Appel S.H. Selegiline is ineffective in a collaborative double-blind, placebo-controlled trial for treatment of amyotrophic lateral sclerosis. Arch. Neurol. 1998;55:93&#x2013;96. doi: 10.1001/archneur.55.1.93.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.55.1.93</ArticleId><ArticleId IdType="pubmed">9443715</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo F., Sandhu A.F., Rungratanawanich W., Williams G.E., Akbar M., Zhou S., Song B.J., Wang X. Melatonin and autophagy in aging-related neurodegenerative diseases. Int. J. Mol. Sci. 2020;21:7174. doi: 10.3390/ijms21197174.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21197174</ArticleId><ArticleId IdType="pmc">PMC7584015</ArticleId><ArticleId IdType="pubmed">32998479</ArticleId></ArticleIdList></Reference><Reference><Citation>Weishaupt J.H., Bartels C., P&#xf6;lking E., Dietrich J., Rohde G., Poeggeler B., Mertens N., Sperling S., Bohn M., H&#xfc;ther G., et al. Reduced oxidative damage in ALS by high-dose enteral melatonin treatment. J. Pineal Res. 2006;41:313&#x2013;323. doi: 10.1111/j.1600-079X.2006.00377.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-079X.2006.00377.x</ArticleId><ArticleId IdType="pubmed">17014688</ArticleId></ArticleIdList></Reference><Reference><Citation>Bald E.M., Nance C.S., Schultz J.L. Melatonin may slow disease progression in amyotrophic lateral sclerosis: Findings from the pooled resource open-access ALS clinic trials database. Muscle Nerve. 2021;63:572&#x2013;576. doi: 10.1002/mus.27168.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.27168</ArticleId><ArticleId IdType="pmc">PMC8842494</ArticleId><ArticleId IdType="pubmed">33428242</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi E.S., Dokholyan N.V. SOD1 oligomers in amyotrophic lateral sclerosis. Curr. Opin. Struct. Biol. 2021;66:225&#x2013;230. doi: 10.1016/j.sbi.2020.12.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.sbi.2020.12.002</ArticleId><ArticleId IdType="pmc">PMC7965251</ArticleId><ArticleId IdType="pubmed">33465527</ArticleId></ArticleIdList></Reference><Reference><Citation>Eleutherio E.C.A., Silva Magalh&#xe3;es R.S., de Ara&#xfa;jo Brasil A., Monteiro Neto J.R., de Holanda Paranhos L. SOD1, more than just an antioxidant. Arch. Biochem. Biophys. 2021;697:108701. doi: 10.1016/j.abb.2020.108701.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.abb.2020.108701</ArticleId><ArticleId IdType="pubmed">33259795</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith R.A., Milleri T.M., Yamanaka K., Monia B.P., Condon T.P., Hung G., Lobsiger C.S., Ward C.M., McAlonis-Downes M., Wei H., et al. Antisense oligonucleotide therapy for neurodegenerative disease. J. Clin. Investig. 2006;116:2290&#x2013;2296. doi: 10.1172/JCI25424.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI25424</ArticleId><ArticleId IdType="pmc">PMC1518790</ArticleId><ArticleId IdType="pubmed">16878173</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller T.M., Pestronk A., David W., Rothstein J., Simpson E., Appel S.H., Andres P.L., Mahoney K., Allred P., Alexander K., et al. An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: A phase 1, randomised, first-in-man study. Lancet Neurol. 2013;12:435&#x2013;442. doi: 10.1016/S1474-4422(13)70061-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(13)70061-9</ArticleId><ArticleId IdType="pmc">PMC3712285</ArticleId><ArticleId IdType="pubmed">23541756</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller T., Cudkowitz M., Shaw P. Safety, PK, PD, and exploratory efficacy in single and multiple dose study of a SOD1 antisense oligonucleotide (BIIB067) administered to participants with ALS; Proceedings of the American Academy of Neurology 71st Annual Meeting; Philadelphia, PA, USA. 4&#x2013;10 May 2019.</Citation></Reference><Reference><Citation>Kieran D., Kalmar B., Dick J.R., Riddoch-Contreras J., Burnstock G., Greensmith L. Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS mice. Nat. Med. 2004;10:402&#x2013;405. doi: 10.1038/nm1021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm1021</ArticleId><ArticleId IdType="pubmed">15034571</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalmar B., Lu C.H., Greensmith L. The role of heat shock proteins in Amyotrophic Lateral Sclerosis: The therapeutic potential of Arimoclomol. Pharmacol. Ther. 2014;141:40&#x2013;54. doi: 10.1016/j.pharmthera.2013.08.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pharmthera.2013.08.003</ArticleId><ArticleId IdType="pubmed">23978556</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M., Wuu J., Andersen P.M., Atassi N., David W., Cudkowicz M., Schoenfeld D. Randomized, double-blind, placebo-controlled trial of arimoclomol in rapidly progressive SOD1 ALS. Neurology. 2018;90:e565&#x2013;e574. doi: 10.1212/WNL.0000000000004960.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000004960</ArticleId><ArticleId IdType="pmc">PMC5818014</ArticleId><ArticleId IdType="pubmed">29367439</ArticleId></ArticleIdList></Reference><Reference><Citation>Liscic R.M., Alberici A., Cairns N.J., Romano M., Buratti E. From basic research to the clinic: Innovative therapies for ALS and FTD in the pipeline. Mol. Neurodegener. 2020;15:31. doi: 10.1186/s13024-020-00373-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-020-00373-9</ArticleId><ArticleId IdType="pmc">PMC7268618</ArticleId><ArticleId IdType="pubmed">32487123</ArticleId></ArticleIdList></Reference><Reference><Citation>Crippa V., D&#x2019;Agostino V.G., Cristofani R., Rusmini P., Cicardi M.E., Messi E., Loffredo R., Pancher M., Piccolella M., Galbiati M., et al. Transcriptional induction of the heat shock protein B8 mediates the clearance of misfolded proteins responsible for motor neuron diseases. Sci. Rep. 2016;6:22827. doi: 10.1038/srep22827.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep22827</ArticleId><ArticleId IdType="pmc">PMC4785366</ArticleId><ArticleId IdType="pubmed">26961006</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandrioli J., Crippa V., Cereda C., Bonetto V., Zucchi E., Gessani A., Ceroni M., Chio A., D&#x2019;Amico R., Monsurr&#xf2; M.R., et al. Proteostasis and ALS: Protocol for a phase II, randomised, double-blind, placebo-controlled, multicentre clinical trial for colchicine in ALS (Co-ALS) BMJ Open. 2019;9:e028486. doi: 10.1136/bmjopen-2018-028486.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2018-028486</ArticleId><ArticleId IdType="pmc">PMC6549675</ArticleId><ArticleId IdType="pubmed">31152038</ArticleId></ArticleIdList></Reference><Reference><Citation>Nikseresht S., Hilton J.B.W., Kysenius K., Liddell J.R., Crouch P.J. Copper-ATSM as a treatment for ALS: Support from mutant SOD1 models and beyond. Life. 2020;10:271. doi: 10.3390/life10110271.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/life10110271</ArticleId><ArticleId IdType="pmc">PMC7694234</ArticleId><ArticleId IdType="pubmed">33158182</ArticleId></ArticleIdList></Reference><Reference><Citation>McAllum E.J., Lim N.K., Hickey J.L., Paterson B.M., Donnelly P.S., Li Q.X., Liddell J.R., Barnham K.J., White A.R., Crouch P.J. Therapeutic effects of CuII(atsm) in the SOD1-G37R mouse model of amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Front. Degener. 2013;14:586&#x2013;590. doi: 10.3109/21678421.2013.824000.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2013.824000</ArticleId><ArticleId IdType="pubmed">23952668</ArticleId></ArticleIdList></Reference><Reference><Citation>Hilton J.B.W., Kysenius K., Liddell J.R., Rautengarten C., Mercer S.W., Paul B., Beckman J.S., McLean C., White A.R., Donnelly P.S., et al. Disrupted copper availability in sporadic ALS: Implications for CuII(atsm) as a treatment option. BioRxiv. 2020 doi: 10.1101/2020.04.17.047704.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.04.17.047704</ArticleId></ArticleIdList></Reference><Reference><Citation>Lange D.J., Andersen P.M., Remanan R., Marklund S., Benjamin D. Pyrimethamine decreases levels of SOD1 in leukocytes and cerebrospinal fluid of ALS patients: A phase I pilot study. Amyotroph. Lateral Scler. Front. Degener. 2013;14:199&#x2013;204. doi: 10.3109/17482968.2012.724074.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482968.2012.724074</ArticleId><ArticleId IdType="pubmed">22985433</ArticleId></ArticleIdList></Reference><Reference><Citation>Lange D.J., Shahbazi M., Silani V., Ludolph A.C., Weishaupt J.H., Ajroud-Driss S., Fields K.G., Remanan R., Appel S.H., Morelli C., et al. Pyrimethamine significantly lowers cerebrospinal fluid Cu/Zn superoxide dismutase in amyotrophic lateral sclerosis patients with SOD1 mutations. Ann. Neurol. 2017;81:837&#x2013;848. doi: 10.1002/ana.24950.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24950</ArticleId><ArticleId IdType="pmc">PMC5518287</ArticleId><ArticleId IdType="pubmed">28480639</ArticleId></ArticleIdList></Reference><Reference><Citation>Capper M.J., Wright G.S.A., Barbieri L., Luchinat E., Mercatelli E., McAlary L., Yerbury J.J., O&#x2019;Neill P.M., Antonyuk S.V., Banci L., et al. The cysteine-reactive small molecule ebselen facilitates effective SOD1 maturation. Nat. Commun. 2018;9:1693. doi: 10.1038/s41467-018-04114-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-04114-x</ArticleId><ArticleId IdType="pmc">PMC5923229</ArticleId><ArticleId IdType="pubmed">29703933</ArticleId></ArticleIdList></Reference><Reference><Citation>Jhanji R., Behl T., Sehgal A., Bungau S. Mitochondrial dysfunction and traffic jams in amyotrophic lateral sclerosis. Mitochondrion. 2021;58:102&#x2013;110. doi: 10.1016/j.mito.2021.02.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mito.2021.02.008</ArticleId><ArticleId IdType="pubmed">33639271</ArticleId></ArticleIdList></Reference><Reference><Citation>Bordet T., Buisson B., Michaud M., Drouot C., Gal&#xe9;a P., Delaage P., Akentieva N.P., Evers A.S., Covey D.F., Ostuni M.A., et al. Identification and characterization of cholest-4-en-3-one, oxime (TRO19622), a novel drug candidate for amyotrophic lateral sclerosis. J. Pharmacol. Exp. Ther. 2007;322:709&#x2013;720. doi: 10.1124/jpet.107.123000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/jpet.107.123000</ArticleId><ArticleId IdType="pubmed">17496168</ArticleId></ArticleIdList></Reference><Reference><Citation>Lenglet T., Lacomblez L., Abitbol J.L., Ludolph A., Mora J.S., Robberecht W., Shaw P.J., Pruss R.M., Cuvier V., Meininger V., et al. A phase II-III trial of olesoxime in subjects with amyotrophic lateral sclerosis. Eur. J. Neurol. 2014;21:529&#x2013;536. doi: 10.1111/ene.12344.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.12344</ArticleId><ArticleId IdType="pubmed">24447620</ArticleId></ArticleIdList></Reference><Reference><Citation>Klivenyi P., Ferrante R.J., Matthews R.T., Bogdanov M.B., Klein A.M., Andreassen O.A., Mueller G., Wermer M., Kaddurah-Daouk R., Beal M.F. Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nat. Med. 1999;5:347&#x2013;350. doi: 10.1038/6568.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/6568</ArticleId><ArticleId IdType="pubmed">10086395</ArticleId></ArticleIdList></Reference><Reference><Citation>Groeneveld G.J., Veldink J.H., van der Tweel I., Kalmijn S., Beijer C., de Visser M., Wokke J.H., Franssen H., van den Berg L.H. A randomized sequential trial of creatine in amyotrophic lateral sclerosis. Ann. Neurol. 2003;53:437&#x2013;445. doi: 10.1002/ana.10554.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.10554</ArticleId><ArticleId IdType="pubmed">12666111</ArticleId></ArticleIdList></Reference><Reference><Citation>Shefner J.M., Cudkowicz M.E., Schoenfeld D., Conrad T., Taft J., Chilton M., Urbinelli L., Qureshi M., Zhang H., Pestronk A., et al. A clinical trial of creatine in ALS. Neurology. 2004;63:1656&#x2013;1661. doi: 10.1212/01.WNL.0000142992.81995.F0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.WNL.0000142992.81995.F0</ArticleId><ArticleId IdType="pubmed">15534251</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenfeld J., King R.M., Jackson C.E., Bedlack R.S., Barohn R.J., Dick A., Phillips L.H., Chapin J., Gelinas D.F., Lou J.S. Creatine monohydrate in ALS: Effects on strength, fatigue, respiratory status and ALSFRS. Amyotroph. Lateral Scler. 2008;9:266&#x2013;272. doi: 10.1080/17482960802028890.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17482960802028890</ArticleId><ArticleId IdType="pmc">PMC2631354</ArticleId><ArticleId IdType="pubmed">18608103</ArticleId></ArticleIdList></Reference><Reference><Citation>Matthews R.T., Yang L., Browne S., Baik M., Beal M.F. Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects. Proc. Natl. Acad. Sci. USA. 1998;95:8892&#x2013;8897. doi: 10.1073/pnas.95.15.8892.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.95.15.8892</ArticleId><ArticleId IdType="pmc">PMC21173</ArticleId><ArticleId IdType="pubmed">9671775</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufmann P., Thompson J.L., Levy G., Buchsbaum R., Shefner J., Krivickas L.S., Katz J., Rollins Y., Barohn R.J., Jackson C.E., et al. Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III. Ann. Neurol. 2009;66:235&#x2013;244. doi: 10.1002/ana.21743.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21743</ArticleId><ArticleId IdType="pmc">PMC2854625</ArticleId><ArticleId IdType="pubmed">19743457</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramalho T.C., de Castro A.A., Tavares T.S., Silva M.C., Silva D.R., Cesar P.H., Santos L.A., da Cunha E.F.F., Nepovimova E., Kuca K. Insights into the pharmaceuticals and mechanisms of neurological orphan diseases: Current status and future expectations. Prog. Neurobiol. 2018;169:135&#x2013;157. doi: 10.1016/j.pneurobio.2018.06.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pneurobio.2018.06.011</ArticleId><ArticleId IdType="pubmed">29981392</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng Kee Kwong K.C., Mehta A.R., Nedergaard M., Chandran S. Defining novel functions for cerebrospinal fluid in ALS pathophysiology. Acta Neuropathol. Commun. 2020;8:140. doi: 10.1186/s40478-020-01018-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-020-01018-0</ArticleId><ArticleId IdType="pmc">PMC7439665</ArticleId><ArticleId IdType="pubmed">32819425</ArticleId></ArticleIdList></Reference><Reference><Citation>Silva-Hucha S., Pastor A.M., Morcuende S. Neuroprotective effect of vascular endothelial growth factor on motoneurons of the oculomotor system. Int. J. Mol. Sci. 2021;22:814. doi: 10.3390/ijms22020814.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22020814</ArticleId><ArticleId IdType="pmc">PMC7830098</ArticleId><ArticleId IdType="pubmed">33467517</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheah B.C., Vucic S., Krishnan A.V., Kiernan M.C. Riluzole, neuroprotection and amyotrophic lateral sclerosis. Curr. Med. Chem. 2010;17:1942&#x2013;1959. doi: 10.2174/092986710791163939.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/092986710791163939</ArticleId><ArticleId IdType="pubmed">20377511</ArticleId></ArticleIdList></Reference><Reference><Citation>Mignani S., Majoral J.P., Desaphy J.F., Lentini G. From Riluzole to dexpramipexole via substituted-benzothiazole derivatives for amyotrophic lateral sclerosis disease treatment: Case studies. Molecules. 2020;25:3320. doi: 10.3390/molecules25153320.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules25153320</ArticleId><ArticleId IdType="pmc">PMC7435757</ArticleId><ArticleId IdType="pubmed">32707914</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathis S., Couratier P., Julian A., Vallat J.M., Corcia P., Le Masson G. Management and therapeutic perspectives in amyotrophic lateral sclerosis. Expert Rev. Neurother. 2017;17:263&#x2013;276. doi: 10.1080/14737175.2016.1227705.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14737175.2016.1227705</ArticleId><ArticleId IdType="pubmed">27644548</ArticleId></ArticleIdList></Reference><Reference><Citation>Bensimon G., Lacomblez L., Meininger V. ALS/Riluzole Study Group. A controlled trial of riluzole in amyotrophic lateral sclerosis. N. Engl. J. Med. 1994;330:585&#x2013;591. doi: 10.1056/NEJM199403033300901.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199403033300901</ArticleId><ArticleId IdType="pubmed">8302340</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacomblez L., Bensimon G., Leigh P.N., Guillet P., Powe L., Durrleman S., Delumeau J.C., Meininger V. A confirmatory dose-ranging study of riluzole in ALS. ALS/Riluzole Study Group-II. Neurology. 1996;47:S242&#x2013;S250. doi: 10.1212/WNL.47.6_Suppl_4.242S.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.47.6_Suppl_4.242S</ArticleId><ArticleId IdType="pubmed">8959996</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorst J., Ludolph A.C., Huebers A. Disease-modifying and symptomatic treatment of amyotrophic lateral sclerosis. Ther. Adv. Neurol. Disord. 2017;11:1756285617734734. doi: 10.1177/1756285617734734.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1756285617734734</ArticleId><ArticleId IdType="pmc">PMC5784546</ArticleId><ArticleId IdType="pubmed">29399045</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar V., Islam A., Hassan M.I., Ahmad F. Therapeutic progress in amyotrophic lateral sclerosis-beginning to learning. Eur. J. Med. Chem. 2016;121:903&#x2013;917. doi: 10.1016/j.ejmech.2016.06.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejmech.2016.06.017</ArticleId><ArticleId IdType="pubmed">27372371</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller R.G., Moore D.H., 2nd, Gelinas D.F., Dronsky V., Mendoza M., Barohn R.J., Bryan W., Ravits J., Yuen E., Neville H., et al. Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis. Neurology. 2001;56:843&#x2013;848. doi: 10.1212/WNL.56.7.843.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.56.7.843</ArticleId><ArticleId IdType="pubmed">11294919</ArticleId></ArticleIdList></Reference><Reference><Citation>Errante L.D., Petroff O.A. Acute effects of gabapentin and pregabalin on rat forebrain cellular GABA, glutamate, and glutamine concentrations. Seizure. 2003;12:300&#x2013;306. doi: 10.1016/S1059-1311(02)00295-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1059-1311(02)00295-9</ArticleId><ArticleId IdType="pubmed">12810343</ArticleId></ArticleIdList></Reference><Reference><Citation>Cudkowicz M.E., Shefner J.M., Schoenfeld D.A., Brown R.H., Jr., Johnson H., Qureshi M., Jacobs M., Rothstein J.D., Appel S.H., Pascuzzi R.M., et al. A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis. Neurology. 2003;61:456&#x2013;464. doi: 10.1212/WNL.61.4.456.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.61.4.456</ArticleId><ArticleId IdType="pubmed">12939417</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanka V., Cudkowicz M. Therapy development for ALS: Lessons learned and path forward. Amyotroph. Lateral Scler. 2008;9:131&#x2013;140. doi: 10.1080/17482960802112819.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17482960802112819</ArticleId><ArticleId IdType="pubmed">18574756</ArticleId></ArticleIdList></Reference><Reference><Citation>Akamatsu M., Yamashita T., Hirose N., Teramoto S., Kwak S. The AMPA receptor antagonist perampanel robustly rescues amyotrophic lateral sclerosis (ALS) pathology in sporadic ALS model mice. Sci. Rep. 2016;6:28649. doi: 10.1038/srep28649.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep28649</ArticleId><ArticleId IdType="pmc">PMC4923865</ArticleId><ArticleId IdType="pubmed">27350567</ArticleId></ArticleIdList></Reference><Reference><Citation>Hotait M., Ismail H.H., Saab G.E., Salameh J.S. An open label pilot study of the safety and tolerability of perampanel in amyotrophic lateral sclerosis. Muscle Nerve. 2021;64:504&#x2013;508. doi: 10.1002/mus.27385.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.27385</ArticleId><ArticleId IdType="pubmed">34322897</ArticleId></ArticleIdList></Reference><Reference><Citation>Aizawa H., Kato H., Oba K., Kawahara T., Okubo Y., Saito T., Naito M., Urushitani M., Tamaoka A., Nakamagoe K., et al. Randomized phase 2 study of perampanel for sporadic amyotrophic lateral sclerosis. J. Neurol. 2022;269:885&#x2013;896. doi: 10.1007/s00415-021-10670-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-021-10670-y</ArticleId><ArticleId IdType="pmc">PMC8782807</ArticleId><ArticleId IdType="pubmed">34191081</ArticleId></ArticleIdList></Reference><Reference><Citation>Paizs M., Tortarolo M., Bendotti C., Engelhardt J.I., Sikl&#xf3;s L. Talampanel reduces the level of motoneuronal calcium in transgenic mutant SOD1 mice only if applied presymptomatically. Amyotroph. Lateral Scler. 2011;12:340&#x2013;344. doi: 10.3109/17482968.2011.584627.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482968.2011.584627</ArticleId><ArticleId IdType="pmc">PMC3231880</ArticleId><ArticleId IdType="pubmed">21623665</ArticleId></ArticleIdList></Reference><Reference><Citation>Pascuzzi R.M., Shefner J., Chappell A.S., Bjerke J.S., Tamura R., Chaudhry V., Clawson L., Haas L., Rothstein J.D. A phase II trial of talampanel in subjects with amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. 2010;11:266&#x2013;271. doi: 10.3109/17482960903307805.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482960903307805</ArticleId><ArticleId IdType="pubmed">19961264</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang R., Zhang D. Memantine prolongs survival in an amyotrophic lateral sclerosis mouse model. Eur. J. Neurosci. 2005;22:2376&#x2013;2380. doi: 10.1111/j.1460-9568.2005.04431.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1460-9568.2005.04431.x</ArticleId><ArticleId IdType="pubmed">16262676</ArticleId></ArticleIdList></Reference><Reference><Citation>De Carvalho M., Pinto S., Costa J., Evangelista T., Ohana B., Pinto A. A randomized, placebo-controlled trial of memantine for functional disability in amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. 2010;11:456&#x2013;460. doi: 10.3109/17482968.2010.498521.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482968.2010.498521</ArticleId><ArticleId IdType="pubmed">20565333</ArticleId></ArticleIdList></Reference><Reference><Citation>Gredal O., Werdelin L., Bak S., Christensen P.B., Boysen G., Kristensen M.O., Jespersen J.H., Regeur L., Hinge H.H., Jensen T.S. A clinical trial of dextromethorphan in amyotrophic lateral sclerosis. Acta Neurol. Scand. 1997;96:8&#x2013;13. doi: 10.1111/j.1600-0404.1997.tb00231.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-0404.1997.tb00231.x</ArticleId><ArticleId IdType="pubmed">9262126</ArticleId></ArticleIdList></Reference><Reference><Citation>Brimson J.M., Brimson S., Chomchoei C., Tencomnao T. Using sigma-ligands as part of a multi-receptor approach to target diseases of the brain. Expert Opin. Ther. Targets. 2020;24:1009&#x2013;1028. doi: 10.1080/14728222.2020.1805435.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14728222.2020.1805435</ArticleId><ArticleId IdType="pubmed">32746649</ArticleId></ArticleIdList></Reference><Reference><Citation>Huynh W., Ahmed R., Mahoney C.J., Nguyen C., Tu S., Caga J., Loh P., Lin C.S., Kiernan M.C. The impact of cognitive and behavioral impairment in amyotrophic lateral sclerosis. Expert Rev. Neurother. 2020;20:281&#x2013;293. doi: 10.1080/14737175.2020.1727740.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14737175.2020.1727740</ArticleId><ArticleId IdType="pubmed">32031423</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothstein J.D., Patel S., Regan M.R., Haenggeli C., Huang Y.H., Bergles D.E., Jin L., Dykes Hoberg M., Vidensky S., Chung D.S., et al. Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature. 2005;433:73&#x2013;77. doi: 10.1038/nature03180.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature03180</ArticleId><ArticleId IdType="pubmed">15635412</ArticleId></ArticleIdList></Reference><Reference><Citation>Cudkowicz M.E., Titus S., Kearney M., Yu H., Sherman A., Schoenfeld D., Hayden D., Shui A., Brooks B., Conwit R., et al. Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: A multi-stage, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2014;13:1083&#x2013;1091. doi: 10.1016/S1474-4422(14)70222-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(14)70222-4</ArticleId><ArticleId IdType="pmc">PMC4216315</ArticleId><ArticleId IdType="pubmed">25297012</ArticleId></ArticleIdList></Reference><Reference><Citation>Yacila G., Sari Y. Potential therapeutic drugs and methods for the treatment of amyotrophic lateral sclerosis. Curr. Med. Chem. 2014;21:3583&#x2013;3593. doi: 10.2174/0929867321666140601162710.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/0929867321666140601162710</ArticleId><ArticleId IdType="pmc">PMC4182116</ArticleId><ArticleId IdType="pubmed">24934355</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller R.G., Smith S.A., Murphy J.R., Brinkmann J.R., Graves J., Mendoza M., Sands M.L., Ringel S.P. A clinical trial of verapamil in amyotrophic lateral sclerosis. Muscle Nerve. 1996;19:511&#x2013;515. doi: 10.1002/mus.880190405.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.880190405</ArticleId><ArticleId IdType="pubmed">8622731</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller R.G., Shepherd R., Dao H., Khramstov A., Mendoza M., Graves J., Smith S. Controlled trial of nimodipine in amyotrophic lateral sclerosis. Neuromuscul. Disord. 1996;6:101&#x2013;104. doi: 10.1016/0960-8966(95)00024-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0960-8966(95)00024-0</ArticleId><ArticleId IdType="pubmed">8664560</ArticleId></ArticleIdList></Reference><Reference><Citation>Shibuya K., Misawa S., Kimura H., Noto Y., Sato Y., Sekiguchi Y., Iwai Y., Mitsuma S., Beppu M., Watanabe K., et al. A single blind randomized controlled clinical trial of mexiletine in amyotrophic lateral sclerosis: Efficacy and safety of sodium channel blocker phase II trial. Amyotroph. Lateral Scler. Front. Degener. 2015;16:353&#x2013;358. doi: 10.3109/21678421.2015.1038277.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2015.1038277</ArticleId><ArticleId IdType="pubmed">25960085</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiss M.D., Macklin E.A., Simmons Z., Knox A.S., Greenblatt D.J., Atassi N., Graves M., Parziale N., Salameh J.S., Quinn C., et al. A randomized trial of mexiletine in ALS: Safety and effects on muscle cramps and progression. Neurology. 2016;86:1474&#x2013;1481. doi: 10.1212/WNL.0000000000002507.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000002507</ArticleId><ArticleId IdType="pmc">PMC4836879</ArticleId><ArticleId IdType="pubmed">26911633</ArticleId></ArticleIdList></Reference><Reference><Citation>Oskarsson B., Moore D., Mozaffar T., Ravits J., Wiedau-Pazos M., Parziale N., Joyce N.C., Mandeville R., Goyal N., Cudkowicz M.E., et al. Mexiletine for muscle cramps in amyotrophic lateral sclerosis: A randomized, double-blind crossover trial. Muscle Nerve. 2018;58:42&#x2013;48. doi: 10.1002/mus.26117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.26117</ArticleId><ArticleId IdType="pmc">PMC6126993</ArticleId><ArticleId IdType="pubmed">29510461</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldsmith D.R., Wagstaff A.J., Ibbotson T., Perry C.M. Lamotrigine: A review of its use in bipolar disorder. Drugs. 2003;63:2029&#x2013;2050. doi: 10.2165/00003495-200363190-00009.</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/00003495-200363190-00009</ArticleId><ArticleId IdType="pubmed">12962521</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryberg H., Askmark H., Persson L.I. A double-blind randomized clinical trial in amyotrophic lateral sclerosis using lamotrigine: Effects on CSF glutamate, aspartate, branched-chain amino acid levels and clinical parameters. Acta Neurol. Scand. 2003;108:1&#x2013;8. doi: 10.1034/j.1600-0404.2003.00111.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1034/j.1600-0404.2003.00111.x</ArticleId><ArticleId IdType="pubmed">12807386</ArticleId></ArticleIdList></Reference><Reference><Citation>Beattie K., Phadke G., Novakovic J. Lamotrigine. In: Brittain H.G., editor. Profiles of Drug Substances, Excipients and Related Methodology. Volume 37. Elsevier; Amsterdam, The Netherlands: 2012. pp. 245&#x2013;285.</Citation><ArticleIdList><ArticleId IdType="pubmed">22469320</ArticleId></ArticleIdList></Reference><Reference><Citation>Wainger B.J., Kiskinis E., Mellin C., Wiskow O., Han S.S., Sandoe J., Perez N.P., Williams L.A., Lee S., Boulting G., et al. Intrinsic membrane hyperexcitability of amyotrophic lateral sclerosis patient-derived motor neurons. Cell Rep. 2014;7:1&#x2013;11. doi: 10.1016/j.celrep.2014.03.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2014.03.019</ArticleId><ArticleId IdType="pmc">PMC4023477</ArticleId><ArticleId IdType="pubmed">24703839</ArticleId></ArticleIdList></Reference><Reference><Citation>Wainger B.J., Macklin E.A., Vucic S., McIlduff C.E., Paganoni S., Maragakis N.J., Bedlack R., Goyal N.A., Rutkove S.B., Lange D.J., et al. Effect of ezogabine on cortical and spinal motor neuron excitability in amyotrophic lateral sclerosis: A randomized clinical trial. JAMA Neurol. 2021;78:186&#x2013;196. doi: 10.1001/jamaneurol.2020.4300.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2020.4300</ArticleId><ArticleId IdType="pmc">PMC7684515</ArticleId><ArticleId IdType="pubmed">33226425</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaji R., Kodama M., Imamura A., Hashida T., Kohara N., Ishizu M., Inui K., Kimura J. Effect of ultrahigh-dose methylcobalamin on compound muscle action potentials in amyotrophic lateral sclerosis: A double-blind controlled study. Muscle Nerve. 1998;21:1775&#x2013;1778. doi: 10.1002/(SICI)1097-4598(199812)21:12&lt;1775::AID-MUS22&gt;3.0.CO;2-V.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1097-4598(199812)21:12&lt;1775::AID-MUS22&gt;3.0.CO;2-V</ArticleId><ArticleId IdType="pubmed">9843082</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikeda K., Iwasaki Y., Kaji R. Neuroprotective effect of ultra-high dose methylcobalamin in wobbler mouse model of amyotrophic lateral sclerosis. J. Neurol. Sci. 2015;354:70&#x2013;74. doi: 10.1016/j.jns.2015.04.052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2015.04.052</ArticleId><ArticleId IdType="pubmed">25982504</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaji R., Imai T., Iwasaki Y., Okamoto K., Nakagawa M., Ohashi Y., Takase T., Hanada T., Shimizu H., Tashiro K., et al. Ultra-high-dose methylcobalamin in amyotrophic lateral sclerosis: A long-term phase II/III randomised controlled study. J. Neurol. Neurosurg. Psychiatry. 2019;90:451&#x2013;457. doi: 10.1136/jnnp-2018-319294.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2018-319294</ArticleId><ArticleId IdType="pmc">PMC6581107</ArticleId><ArticleId IdType="pubmed">30636701</ArticleId></ArticleIdList></Reference><Reference><Citation>Levine B., Sinha S., Kroemer G. Bcl-2 family members: Dual regulators of apoptosis and autophagy. Autophagy. 2008;4:600&#x2013;606. doi: 10.4161/auto.6260.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/auto.6260</ArticleId><ArticleId IdType="pmc">PMC2749577</ArticleId><ArticleId IdType="pubmed">18497563</ArticleId></ArticleIdList></Reference><Reference><Citation>Amin A., Perera N.D., Beart P.M., Turner B.J., Shabanpoor F. Amyotrophic lateral sclerosis and autophagy: Dysfunction and therapeutic targeting. Cells. 2020;9:2413. doi: 10.3390/cells9112413.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells9112413</ArticleId><ArticleId IdType="pmc">PMC7694295</ArticleId><ArticleId IdType="pubmed">33158177</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J. Regulation of cell death by the Abl tyrosine kinase. Oncogene. 2000;19:5643&#x2013;5650. doi: 10.1038/sj.onc.1203878.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.onc.1203878</ArticleId><ArticleId IdType="pubmed">11114745</ArticleId></ArticleIdList></Reference><Reference><Citation>Schlatterer S.D., Acker C.M., Davies P. c-Abl in neurodegenerative disease. J. Mol. Neurosci. 2011;45:445&#x2013;452. doi: 10.1007/s12031-011-9588-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12031-011-9588-1</ArticleId><ArticleId IdType="pmc">PMC3329755</ArticleId><ArticleId IdType="pubmed">21728062</ArticleId></ArticleIdList></Reference><Reference><Citation>Karagiannis P., Inoue H. ALS, a cellular whodunit on motor neuron degeneration. Mol. Cell Neurosci. 2020;107:103524. doi: 10.1016/j.mcn.2020.103524.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mcn.2020.103524</ArticleId><ArticleId IdType="pubmed">32629110</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim B.W., Jeong Y.E., Wong M., Martin L.J. DNA damage accumulates and responses are engaged in human ALS brain and spinal motor neurons and DNA repair is activatable in iPSC-derived motor neurons with SOD1 mutations. Acta Neuropathol. Commun. 2020;8:7. doi: 10.1186/s40478-019-0874-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-019-0874-4</ArticleId><ArticleId IdType="pmc">PMC6995159</ArticleId><ArticleId IdType="pubmed">32005289</ArticleId></ArticleIdList></Reference><Reference><Citation>Rojas F., Gonzalez D., Cortes N., Ampuero E., Hern&#xe1;ndez D.E., Fritz E., Abarzua S., Martinez A., Elorza A.A., Alvarez A., et al. Reactive oxygen species trigger motoneuron death in non-cell-autonomous models of ALS through activation of c-Abl signaling. Front. Cell Neurosci. 2015;9:203. doi: 10.3389/fncel.2015.00203.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2015.00203</ArticleId><ArticleId IdType="pmc">PMC4460879</ArticleId><ArticleId IdType="pubmed">26106294</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsumata R., Ishigaki S., Katsuno M., Kawai K., Sone J., Huang Z., Adachi H., Tanaka F., Urano F., Sobue G. c-Abl inhibition delays motor neuron degeneration in the G93A mouse, an animal model of amyotrophic lateral sclerosis. PLoS ONE. 2012;7:e46185. doi: 10.1371/journal.pone.0046185.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0046185</ArticleId><ArticleId IdType="pmc">PMC3458026</ArticleId><ArticleId IdType="pubmed">23049975</ArticleId></ArticleIdList></Reference><Reference><Citation>Imamura K., Izumi Y., Watanabe A., Tsukita K., Woltjen K., Yamamoto T., Hotta A., Kondo T., Kitaoka S., Ohta A., et al. The Src/c-Abl pathway is a potential therapeutic target in amyotrophic lateral sclerosis. Sci. Transl. Med. 2017;9:eaaf3962. doi: 10.1126/scitranslmed.aaf3962.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aaf3962</ArticleId><ArticleId IdType="pubmed">28539470</ArticleId></ArticleIdList></Reference><Reference><Citation>Imamura K., Izumi Y., Banno H., Uozumi R., Morita S., Egawa N., Ayaki T., Nagai M., Nishiyama K., Watanabe Y., et al. Induced pluripotent stem cell-based Drug Repurposing for Amyotrophic lateral sclerosis Medicine (iDReAM) study: Protocol for a phase I dose escalation study of bosutinib for amyotrophic lateral sclerosis patients. BMJ Open. 2019;9:e033131. doi: 10.1136/bmjopen-2019-033131.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2019-033131</ArticleId><ArticleId IdType="pmc">PMC7003406</ArticleId><ArticleId IdType="pubmed">31796494</ArticleId></ArticleIdList></Reference><Reference><Citation>Amaral J.D., Viana R.J., Ramalho R.M., Steer C.J., Rodrigues C.M. Bile acids: Regulation of apoptosis by ursodeoxycholic acid. J. Lipid Res. 2009;50:1721&#x2013;1734. doi: 10.1194/jlr.R900011-JLR200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1194/jlr.R900011-JLR200</ArticleId><ArticleId IdType="pmc">PMC2724780</ArticleId><ArticleId IdType="pubmed">19417220</ArticleId></ArticleIdList></Reference><Reference><Citation>Elia A.E., Lalli S., Monsurr&#xf2; M.R., Sagnelli A., Taiello A.C., Reggiori B., La Bella V., Tedeschi G., Albanese A. Tauroursodeoxycholic acid in the treatment of patients with amyotrophic lateral sclerosis. Eur. J. Neurol. 2016;23:45&#x2013;52. doi: 10.1111/ene.12664.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.12664</ArticleId><ArticleId IdType="pmc">PMC5024041</ArticleId><ArticleId IdType="pubmed">25664595</ArticleId></ArticleIdList></Reference><Reference><Citation>Palomo V., Nozal V., Rojas-Prats E., Gil C., Martinez A. Protein kinase inhibitors for amyotrophic lateral sclerosis therapy. Br. J. Pharmacol. 2021;178:1316&#x2013;1335. doi: 10.1111/bph.15221.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bph.15221</ArticleId><ArticleId IdType="pubmed">32737989</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandrioli J., D&#x2019;Amico R., Zucchi E., Gessani A., Fini N., Fasano A., Caponnetto C., Chi&#xf2; A., Dalla Bella E., Lunetta C., et al. Rapamycin treatment for amyotrophic lateral sclerosis: Protocol for a phase II randomized, double-blind, placebo-controlled, multicenter, clinical trial (RAP-ALS trial) Medicine. 2018;97:e11119. doi: 10.1097/MD.0000000000011119.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000011119</ArticleId><ArticleId IdType="pmc">PMC6024184</ArticleId><ArticleId IdType="pubmed">29901635</ArticleId></ArticleIdList></Reference><Reference><Citation>Fornai F., Longone P., Cafaro L., Kastsiuchenka O., Ferrucci M., Manca M.L., Lazzeri G., Spalloni A., Bellio N., Lenzi P., et al. Lithium delays progression of amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. USA. 2008;105:2052&#x2013;2057. doi: 10.1073/pnas.0708022105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0708022105</ArticleId><ArticleId IdType="pmc">PMC2538879</ArticleId><ArticleId IdType="pubmed">18250315</ArticleId></ArticleIdList></Reference><Reference><Citation>Morrison K.E., Dhariwal S., Hornabrook R., Savage L., Burn D.J., Khoo T.K., Kelly J., Murphy C.L., Al-Chalabi A., et al. UKMND-LiCALS Study Group Lithium in patients with amyotrophic lateral sclerosis (LiCALS): A phase 3 multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2013;12:339&#x2013;345.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3610091</ArticleId><ArticleId IdType="pubmed">23453347</ArticleId></ArticleIdList></Reference><Reference><Citation>Aggarwal S.P., Zinman L., Simpson E., McKinley J., Jackson K.E., Pinto H., Kaufman P., Conwit R.A., Schoenfeld D., Shefner J., et al. Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: A randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010;9:481&#x2013;488. doi: 10.1016/S1474-4422(10)70068-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(10)70068-5</ArticleId><ArticleId IdType="pmc">PMC3071495</ArticleId><ArticleId IdType="pubmed">20363190</ArticleId></ArticleIdList></Reference><Reference><Citation>Sugai F., Yamamoto Y., Miyaguchi K., Zhou Z., Sumi H., Hamasaki T., Goto M., Sakoda S. Benefit of valproic acid in suppressing disease progression of ALS model mice. Eur. J. Neurosci. 2004;20:3179&#x2013;3183. doi: 10.1111/j.1460-9568.2004.03765.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1460-9568.2004.03765.x</ArticleId><ArticleId IdType="pubmed">15579172</ArticleId></ArticleIdList></Reference><Reference><Citation>Piepers S., Veldink J.H., de Jong S.W., van der Tweel I., van der Pol W.L., Uijtendaal E.V., Schelhaas H.J., Scheffer H., de Visser M., de Jong J.M., et al. Randomized sequential trial of valproic acid in amyotrophic lateral sclerosis. Ann. Neurol. 2009;66:227&#x2013;234. doi: 10.1002/ana.21620.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21620</ArticleId><ArticleId IdType="pubmed">19743466</ArticleId></ArticleIdList></Reference><Reference><Citation>Leng Y., Liang M.H., Ren M., Marinova Z., Leeds P., Chuang D.M. Synergistic neuroprotective effects of lithium and valproic acid or other histone deacetylase inhibitors in neurons: Roles of glycogen synthase kinase-3 inhibition. J. Neurosci. 2008;28:2576&#x2013;2588. doi: 10.1523/JNEUROSCI.5467-07.2008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.5467-07.2008</ArticleId><ArticleId IdType="pmc">PMC5241911</ArticleId><ArticleId IdType="pubmed">18322101</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng H.L., Leng Y., Ma C.H., Zhang J., Ren M., Chuang D.M. Combined lithium and valproate treatment delays disease onset, reduces neurological deficits and prolongs survival in an amyotrophic lateral sclerosis mouse model. Neuroscience. 2008;155:567&#x2013;572. doi: 10.1016/j.neuroscience.2008.06.040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2008.06.040</ArticleId><ArticleId IdType="pmc">PMC2709275</ArticleId><ArticleId IdType="pubmed">18640245</ArticleId></ArticleIdList></Reference><Reference><Citation>Boll M.C., Bayliss L., Vargas-Ca&#xf1;as S., Burgos J., Montes S., Pe&#xf1;aloza-Solano G., Rios C., Alcaraz-Zubeldia M. Clinical and biological changes under treatment with lithium carbonate and valproic acid in sporadic amyotrophic lateral sclerosis. J. Neurol. Sci. 2014;340:103&#x2013;108. doi: 10.1016/j.jns.2014.03.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2014.03.005</ArticleId><ArticleId IdType="pubmed">24667005</ArticleId></ArticleIdList></Reference><Reference><Citation>Freeman L.C., Ting J.P. The pathogenic role of the inflammasome in neurodegenerative diseases. J. Neurochem. 2016;136:29&#x2013;38. doi: 10.1111/jnc.13217.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.13217</ArticleId><ArticleId IdType="pubmed">26119245</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang Y., Le W. Differential roles of M1 and M2 microglia in neurodegenerative diseases. Mol. Neurobiol. 2016;53:1181&#x2013;1194. doi: 10.1007/s12035-014-9070-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-014-9070-5</ArticleId><ArticleId IdType="pubmed">25598354</ArticleId></ArticleIdList></Reference><Reference><Citation>Du L., Zhang Y., Chen Y., Zhu J., Yang Y., Zhang H.L. Role of microglia in neurological disorders and their potentials as a therapeutic target. Mol. Neurobiol. 2017;54:7567&#x2013;7584. doi: 10.1007/s12035-016-0245-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-016-0245-0</ArticleId><ArticleId IdType="pubmed">27830532</ArticleId></ArticleIdList></Reference><Reference><Citation>Geloso M.C., Corvino V., Marchese E., Serrano A., Michetti F., D&#x2019;Ambrosi N. The dual role of microglia in ALS: Mechanisms and therapeutic approaches. Front. Aging Neurosci. 2017;9:242. doi: 10.3389/fnagi.2017.00242.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2017.00242</ArticleId><ArticleId IdType="pmc">PMC5524666</ArticleId><ArticleId IdType="pubmed">28790913</ArticleId></ArticleIdList></Reference><Reference><Citation>Kulczy&#x144;ska-Przybik A., Mroczko P., Dulewicz M., Mroczko B. The implication of reticulons (RTNs) in neurodegenerative diseases: From molecular mechanisms to potential diagnostic and therapeutic approaches. Int. J. Mol. Sci. 2021;22:4630. doi: 10.3390/ijms22094630.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22094630</ArticleId><ArticleId IdType="pmc">PMC8125174</ArticleId><ArticleId IdType="pubmed">33924890</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizwicki M.T., Fiala M., Magpantay L., Aziz N., Sayre J., Liu G., Siani A., Chan D., Martinez-Maza O., Chattopadhyay M., et al. Tocilizumab attenuates inflammation in ALS patients through inhibition of IL6 receptor signaling. Am. J. Neurodegener. Dis. 2012;1:305&#x2013;315.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3560466</ArticleId><ArticleId IdType="pubmed">23383400</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiala M., Mizwicki M.T., Weitzman R., Magpantay L., Nishimoto N. Tocilizumab infusion therapy normalizes inflammation in sporadic ALS patients. Am. J. Neurodegener. Dis. 2013;2:129&#x2013;139.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3703125</ArticleId><ArticleId IdType="pubmed">23844337</ArticleId></ArticleIdList></Reference><Reference><Citation>Milligan C., Atassi N., Babu S., Barohn R.J., Caress J.B., Cudkowicz M.E., Evora A., Hawkins G.A., Wosiski-Kuhn M., Macklin E.A., et al. Tocilizumab is safe and tolerable and reduces C-reactive protein concentrations in the plasma and cerebrospinal fluid of ALS patients. Muscle Nerve. 2021;64:309&#x2013;320. doi: 10.1002/mus.27339.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.27339</ArticleId><ArticleId IdType="pubmed">34075589</ArticleId></ArticleIdList></Reference><Reference><Citation>Maier A., Deigendesch N., M&#xfc;ller K., Weishaupt J.H., Krannich A., R&#xf6;hle R., Meissner F., Molawi K., M&#xfc;nch C., Holm T., et al. Interleukin-1 antagonist anakinra in amyotrophic lateral sclerosis-A Pilot Study. PLoS ONE. 2015;10:e0139684. doi: 10.1371/journal.pone.0139684.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0139684</ArticleId><ArticleId IdType="pmc">PMC4596620</ArticleId><ArticleId IdType="pubmed">26444282</ArticleId></ArticleIdList></Reference><Reference><Citation>Kukharsky M.S., Skvortsova V.I., Bachurin S.O., Buchman V.L. In a search for efficient treatment for amyotrophic lateral sclerosis: Old drugs for new approaches. Med. Res. Rev. 2021;41:2804&#x2013;2822. doi: 10.1002/med.21725.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/med.21725</ArticleId><ArticleId IdType="pubmed">32815157</ArticleId></ArticleIdList></Reference><Reference><Citation>Vahsen B.F., Gray E., Thompson A.G., Ansorge O., Anthony D.C., Cowley S.A., Talbot K., Turner M.R. Non-neuronal cells in amyotrophic lateral sclerosis-from pathogenesis to biomarkers. Nat. Rev. Neurol. 2021;17:333&#x2013;348. doi: 10.1038/s41582-021-00487-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-021-00487-8</ArticleId><ArticleId IdType="pubmed">33927394</ArticleId></ArticleIdList></Reference><Reference><Citation>Trias E., Ibarburu S., Barreto-N&#xfa;&#xf1;ez R., Babdor J., Maciel T.T., Guillo M., Gros L., Dubreuil P., D&#xed;az-Amarilla P., Cassina P., et al. Post-paralysis tyrosine kinase inhibition with masitinib abrogates neuroinflammation and slows disease progression in inherited amyotrophic lateral sclerosis. J. Neuroinflammation. 2016;13:177. doi: 10.1186/s12974-016-0620-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-016-0620-9</ArticleId><ArticleId IdType="pmc">PMC4940876</ArticleId><ArticleId IdType="pubmed">27400786</ArticleId></ArticleIdList></Reference><Reference><Citation>Trias E., King P.H., Si Y., Kwon Y., Varela V., Ibarburu S., Kovacs M., Moura I.C., Beckman J.S., Hermine O., et al. Mast cells and neutrophils mediate peripheral motor pathway degeneration in ALS. JCI Insight. 2018;3:e123249. doi: 10.1172/jci.insight.123249.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.123249</ArticleId><ArticleId IdType="pmc">PMC6237484</ArticleId><ArticleId IdType="pubmed">30282815</ArticleId></ArticleIdList></Reference><Reference><Citation>Mora J.S., Genge A., Chio A., Estol C.J., Chaverri D., Hern&#xe1;ndez M., Mar&#xed;n S., Mascias J., Rodriguez G.E., Povedano M., et al. Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: A randomized clinical trial. Amyotroph. Lateral Scler. Front. Degener. 2020;21:5&#x2013;14. doi: 10.1080/21678421.2019.1632346.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2019.1632346</ArticleId><ArticleId IdType="pubmed">31280619</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y., Wang H., Ying Z., Gao Q. Ibudilast enhances the clearance of SOD1 and TDP-43 aggregates through TFEB-mediated autophagy and lysosomal biogenesis: The new molecular mechanism of ibudilast and its implication for neuroprotective therapy. Biochem. Biophys. Res. Commun. 2020;526:231&#x2013;238. doi: 10.1016/j.bbrc.2020.03.051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2020.03.051</ArticleId><ArticleId IdType="pubmed">32204915</ArticleId></ArticleIdList></Reference><Reference><Citation>Babu S., Hightower B.G., Chan J., Z&#xfc;rcher N.R., Kivis&#xe4;kk P., Tseng C.J., Sanders D.L., Robichaud A., Banno H., Evora A., et al. Ibudilast (MN-166) in amyotrophic lateral sclerosis- An open label, safety and pharmacodynamic trial. Neuroimage Clin. 2021;30:102672. doi: 10.1016/j.nicl.2021.102672.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nicl.2021.102672</ArticleId><ArticleId IdType="pmc">PMC8102622</ArticleId><ArticleId IdType="pubmed">34016561</ArticleId></ArticleIdList></Reference><Reference><Citation>Berry J.D., Paganoni S., Atassi N., Macklin E.A., Goyal N., Rivner M., Simpson E., Appel S., Grasso D.L., Mejia N.I., et al. Phase IIa trial of fingolimod for amyotrophic lateral sclerosis demonstrates acceptable acute safety and tolerability. Muscle Nerve. 2017;56:1077&#x2013;1084. doi: 10.1002/mus.25733.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.25733</ArticleId><ArticleId IdType="pmc">PMC5724488</ArticleId><ArticleId IdType="pubmed">28662296</ArticleId></ArticleIdList></Reference><Reference><Citation>Lynch A.M., Clevel M., Prinjha R., Kumar U., Stubbs R., Wuerthner J. Non-clinical development of ozanezumab: A humanised antibody targeting the amino terminus of neurite outgrowth inhibitor A (Nogo-A) Toxicol. Res. 2015;4:1333. doi: 10.1039/C5TX00179J.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/C5TX00179J</ArticleId></ArticleIdList></Reference><Reference><Citation>Jokic N., Gonzalez de Aguilar J.L., Dimou L., Lin S., Fergani A., Ruegg M.A., Schwab M.E., Dupuis L., Loeffler J.P. The neurite outgrowth inhibitor Nogo-A promotes denervation in an amyotrophic lateral sclerosis model. EMBO Rep. 2006;7:1162&#x2013;1167. doi: 10.1038/sj.embor.7400826.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.embor.7400826</ArticleId><ArticleId IdType="pmc">PMC1679784</ArticleId><ArticleId IdType="pubmed">17039253</ArticleId></ArticleIdList></Reference><Reference><Citation>Scaricamazza S., Salvatori I., Ferri A., Valle C. Skeletal Muscle in ALS: An unappreciated therapeutic opportunity? Cells. 2021;10:525. doi: 10.3390/cells10030525.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10030525</ArticleId><ArticleId IdType="pmc">PMC8000428</ArticleId><ArticleId IdType="pubmed">33801336</ArticleId></ArticleIdList></Reference><Reference><Citation>Meininger V., Pradat P.F., Corse A., Al-Sarraj S., Rix Brooks B., Caress J.B., Cudkowicz M., Kolb S.J., Lange D., Leigh P.N., et al. Safety, pharmacokinetic, and functional effects of the Nogo-A monoclonal antibody in amyotrophic lateral sclerosis: A randomized, first-in-human clinical trial. PLoS ONE. 2014;9:e97803. doi: 10.1371/journal.pone.0097803.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0097803</ArticleId><ArticleId IdType="pmc">PMC4026380</ArticleId><ArticleId IdType="pubmed">24841795</ArticleId></ArticleIdList></Reference><Reference><Citation>Meininger V., Genge A., van den Berg L.H., Robberecht W., Ludolph A., Chio A., Kim S.H., Leigh P.N., Kiernan M.C., Shefner J.M., et al. Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: A randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol. 2017;16:208&#x2013;216. doi: 10.1016/S1474-4422(16)30399-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(16)30399-4</ArticleId><ArticleId IdType="pubmed">28139349</ArticleId></ArticleIdList></Reference><Reference><Citation>Koch J.C., Kuttler J., Maass F., Lengenfeld T., Zielke E., B&#xe4;hr M., Lingor P. Compassionate use of the ROCK inhibitor fasudil in three patients with amyotrophic lateral sclerosis. Front. Neurol. 2020;11:173. doi: 10.3389/fneur.2020.00173.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2020.00173</ArticleId><ArticleId IdType="pmc">PMC7083210</ArticleId><ArticleId IdType="pubmed">32231638</ArticleId></ArticleIdList></Reference><Reference><Citation>Takata M., Tanaka H., Kimura M., Nagahara Y., Tanaka K., Kawasaki K., Seto M., Tsuruma K., Shimazawa M., Hara H. Fasudil, a rho kinase inhibitor, limits motor neuron loss in experimental models of amyotrophic lateral sclerosis. Br. J. Pharmacol. 2013;170:341&#x2013;351. doi: 10.1111/bph.12277.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bph.12277</ArticleId><ArticleId IdType="pmc">PMC3834758</ArticleId><ArticleId IdType="pubmed">23763343</ArticleId></ArticleIdList></Reference><Reference><Citation>Lingor P., Weber M., Camu W., Friede T., Hilgers R., Leha A., Neuwirth C., G&#xfc;nther R., Benatar M., Kuzma-Kozakiewicz M., et al. ROCK-ALS: Protocol for a randomized, placebo-controlled, double-blind phase IIa trial of safety, tolerability and efficacy of the rho kinase (ROCK) inhibitor fasudil in amyotrophic lateral sclerosis. Front. Neurol. 2019;10:293. doi: 10.3389/fneur.2019.00293.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2019.00293</ArticleId><ArticleId IdType="pmc">PMC6446974</ArticleId><ArticleId IdType="pubmed">30972018</ArticleId></ArticleIdList></Reference><Reference><Citation>Wobst H.J., Mack K.L., Brown D.G., Brandon N.J., Shorter J. The clinical trial landscape in amyotrophic lateral sclerosis&#x2014;Past, present, and future. Med. Res. Rev. 2020;40:1352&#x2013;1384. doi: 10.1002/med.21661.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/med.21661</ArticleId><ArticleId IdType="pmc">PMC7417284</ArticleId><ArticleId IdType="pubmed">32043626</ArticleId></ArticleIdList></Reference><Reference><Citation>Hwee D.T., Kennedy A., Ryans J., Russell A.J., Jia Z., Hinken A.C., Morgans D.J., Malik F.I., Jasper J.R. Fast skeletal muscle troponin activator tirasemtiv increases muscle function and performance in the B6SJL-SOD1G93A ALS mouse model. PLoS ONE. 2014;9:e96921. doi: 10.1371/journal.pone.0096921.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0096921</ArticleId><ArticleId IdType="pmc">PMC4013064</ArticleId><ArticleId IdType="pubmed">24805850</ArticleId></ArticleIdList></Reference><Reference><Citation>Shefner J.M., Wolff A.A., Meng L., Bian A., Lee J., Barragan D., Andrews J.A. BENEFIT-ALS Study Group. A randomized, placebo-controlled, double-blind phase IIb trial evaluating the safety and efficacy of tirasemtiv in patients with amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Front. Degener. 2016;17:426&#x2013;435. doi: 10.3109/21678421.2016.1148169.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2016.1148169</ArticleId><ArticleId IdType="pubmed">26982815</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews J.A., Cudkowicz M.E., Hardiman O., Meng L., Bian A., Lee J., Wolff A.A., Malik F.I., Shefner J.M. VITALITY-ALS, a phase III trial of tirasemtiv, a selective fast skeletal muscle troponin activator, as a potential treatment for patients with amyotrophic lateral sclerosis: Study design and baseline characteristics. Amyotroph. Lateral Scler. Front. Degener. 2018;19:259&#x2013;266. doi: 10.1080/21678421.2018.1426770.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2018.1426770</ArticleId><ArticleId IdType="pubmed">29402141</ArticleId></ArticleIdList></Reference><Reference><Citation>Shefner J.M., Andrews J.A., Genge A., Jackson C., Lechtzin N., Miller T.M., Cockroft B.M., Meng L., Wei J., Wolff A.A., et al. A phase 2, double-blind, randomized, dose-ranging trial of reldesemtiv in patients with ALS. Amyotroph. Lateral Scler. Front. Degener. 2021;22:287&#x2013;299. doi: 10.1080/21678421.2020.1822410.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2020.1822410</ArticleId><ArticleId IdType="pmc">PMC8117790</ArticleId><ArticleId IdType="pubmed">32969758</ArticleId></ArticleIdList></Reference><Reference><Citation>MacGowan D.J., Scelsa S.N., Imperato T.E., Liu K.N., Baron P., Polsky B. A controlled study of reverse transcriptase in serum and CSF of HIV-negative patients with ALS. Neurology. 2007;68:1944&#x2013;1946. doi: 10.1212/01.wnl.0000263188.77797.99.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000263188.77797.99</ArticleId><ArticleId IdType="pubmed">17536052</ArticleId></ArticleIdList></Reference><Reference><Citation>McCormick A.L., Brown R.H., Jr., Cudkowicz M.E., Al-Chalabi A., Garson J.A. Quantification of reverse transcriptase in ALS and elimination of a novel retroviral candidate. Neurology. 2008;70:278&#x2013;283. doi: 10.1212/01.wnl.0000297552.13219.b4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000297552.13219.b4</ArticleId><ArticleId IdType="pubmed">18209202</ArticleId></ArticleIdList></Reference><Reference><Citation>Douville R., Liu J., Rothstein J., Nath A. Identification of active loci of a human endogenous retrovirus in neurons of patients with amyotrophic lateral sclerosis. Ann. Neurol. 2011;69:141&#x2013;151. doi: 10.1002/ana.22149.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.22149</ArticleId><ArticleId IdType="pmc">PMC3052883</ArticleId><ArticleId IdType="pubmed">21280084</ArticleId></ArticleIdList></Reference><Reference><Citation>Castanedo-Vazquez D., Bosque-Varela P., Sainz-Pelayo A., Riancho J. Infectious agents and amyotrophic lateral sclerosis: Another piece of the puzzle of motor neuron degeneration. J. Neurol. 2019;266:27&#x2013;36. doi: 10.1007/s00415-018-8919-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-018-8919-3</ArticleId><ArticleId IdType="pubmed">29845377</ArticleId></ArticleIdList></Reference><Reference><Citation>Gold J., Rowe D.B., Kiernan M.C., Vucic S., Mathers S., van Eijk R.P.A., Nath A., Garcia Montojo M., Norato G., Santamaria U.A., et al. Safety and tolerability of Triumeq in amyotrophic lateral sclerosis: The lighthouse trial. Amyotroph. Lateral Scler. Front. Degener. 2019;20:595&#x2013;604. doi: 10.1080/21678421.2019.1632899.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2019.1632899</ArticleId><ArticleId IdType="pubmed">31284774</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagtegaal I.D., Lakke E.A., Marani E. Trophic and tropic factors in the development of the central nervous system. Arch. Physiol. Biochem. 1998;106:161&#x2013;202. doi: 10.1076/apab.106.3.161.4380.</Citation><ArticleIdList><ArticleId IdType="doi">10.1076/apab.106.3.161.4380</ArticleId><ArticleId IdType="pubmed">10099715</ArticleId></ArticleIdList></Reference><Reference><Citation>Zinman L., Cudkowicz M. Emerging targets and treatments in amyotrophic lateral sclerosis. Lancet Neurol. 2011;10:481&#x2013;490. doi: 10.1016/S1474-4422(11)70024-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(11)70024-2</ArticleId><ArticleId IdType="pubmed">21511200</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagel G., Peter R.S., Rosenbohm A., Koenig W., Dupuis L., Rothenbacher D., Ludolph A.C. Association of Insulin-like Growth Factor 1 Concentrations with Risk for and Prognosis of Amyotrophic Lateral Sclerosis&#x2014;Results from the ALS Registry Swabia. Sci. Rep. 2020;10:736. doi: 10.1038/s41598-020-57744-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-57744-x</ArticleId><ArticleId IdType="pmc">PMC6971302</ArticleId><ArticleId IdType="pubmed">31959864</ArticleId></ArticleIdList></Reference><Reference><Citation>Azzouz M., Ralph G.S., Storkebaum E., Walmsley L.E., Mitrophanous K.A., Kingsman S.M., Carmeliet P., Mazarakis N.D. VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. Nature. 2004;429:413&#x2013;417. doi: 10.1038/nature02544.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature02544</ArticleId><ArticleId IdType="pubmed">15164063</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun W., Funakoshi H., Nakamura T. Overexpression of HGF retards disease progression and prolongs life span in a transgenic mouse model of ALS. J. Neurosci. 2002;22:6537&#x2013;6548. doi: 10.1523/JNEUROSCI.22-15-06537.2002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.22-15-06537.2002</ArticleId><ArticleId IdType="pmc">PMC6758174</ArticleId><ArticleId IdType="pubmed">12151533</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitamura K., Nagoshi N., Tsuji O., Matsumoto M., Okano H., Nakamura M. Application of hepatocyte growth factor for acute spinal cord injury: The road from basic studies to human treatment. Int. J. Mol. Sci. 2019;20:1054. doi: 10.3390/ijms20051054.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20051054</ArticleId><ArticleId IdType="pmc">PMC6429374</ArticleId><ArticleId IdType="pubmed">30823442</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Pichon C.E., Dominguez S.L., Solanoy H., Ngu H., Lewin-Koh N., Chen M., Eastham-Anderson J., Watts R., Scearce-Levie K. EGFR inhibitor erlotinib delays disease progression but does not extend survival in the SOD1 mouse model of ALS. PLoS ONE. 2013;8:e62342. doi: 10.1371/journal.pone.0062342.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0062342</ArticleId><ArticleId IdType="pmc">PMC3637182</ArticleId><ArticleId IdType="pubmed">23638043</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen T., Benmohamed R., Arvanites A.C., Ralay Ranaivo H., Morimoto R.I., Ferrante R.J., Watterson D.M., Kirsch D.R., Silverman R.B. Arylsulfanyl pyrazolones block mutant SOD1-G93A aggregation. Potential application for the treatment of amyotrophic lateral sclerosis. Bioorg. Med. Chem. 2011;19:613&#x2013;622. doi: 10.1016/j.bmc.2010.10.052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bmc.2010.10.052</ArticleId><ArticleId IdType="pmc">PMC3014451</ArticleId><ArticleId IdType="pubmed">21095130</ArticleId></ArticleIdList></Reference><Reference><Citation>Neymotin A., Calingasan N.Y., Wille E., Naseri N., Petri S., Damiano M., Liby K.T., Risingsong R., Sporn M., Beal M.F., et al. Neuroprotective effect of Nrf2/ARE activators, CDDO ethylamide and CDDO trifluoroethylamide, in a mouse model of amyotrophic lateral sclerosis. Free Radic. Biol. Med. 2011;51:88&#x2013;96. doi: 10.1016/j.freeradbiomed.2011.03.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2011.03.027</ArticleId><ArticleId IdType="pmc">PMC3109235</ArticleId><ArticleId IdType="pubmed">21457778</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W., Benmohamed R., Arvanites A.C., Morimoto R.I., Ferrante R.J., Kirsch D.R., Silverman R.B. Cyclohexane 1,3-diones and their inhibition of mutant SOD1-dependent protein aggregation and toxicity in PC12 cells. Bioorg. Med. Chem. 2012;20:1029&#x2013;1045. doi: 10.1016/j.bmc.2011.11.039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bmc.2011.11.039</ArticleId><ArticleId IdType="pmc">PMC3259267</ArticleId><ArticleId IdType="pubmed">22189273</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahn S.W., Jeon G.S., Kim M.J., Shon J.H., Kim J.E., Shin J.Y., Kim S.M., Kim S.H., Ye I.H., Lee K.W., et al. Neuroprotective effects of JGK-263 in transgenic SOD1-G93A mice of amyotrophic lateral sclerosis. J. Neurol. Sci. 2014;340:112&#x2013;116. doi: 10.1016/j.jns.2014.03.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2014.03.008</ArticleId><ArticleId IdType="pubmed">24680562</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka K., Kanno T., Yanagisawa Y., Yasutake K., Inoue S., Hirayama N., Ikeda J.E. A novel acylaminoimidazole derivative, WN1316, alleviates disease progression via suppression of glial inflammation in ALS mouse model. PLoS ONE. 2014;9:e87728. doi: 10.1371/journal.pone.0087728.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0087728</ArticleId><ArticleId IdType="pmc">PMC3909264</ArticleId><ArticleId IdType="pubmed">24498180</ArticleId></ArticleIdList></Reference><Reference><Citation>Getter T., Zaks I., Barhum Y., Ben-Zur T., B&#xf6;selt S., Gregoire S., Viskind O., Shani T., Gottlieb H., Green O., et al. A chemical chaperone-based drug candidate is effective in a mouse model of amyotrophic lateral sclerosis (ALS) ChemMedChem. 2015;10:850&#x2013;861. doi: 10.1002/cmdc.201500045.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cmdc.201500045</ArticleId><ArticleId IdType="pubmed">25772747</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>